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Dnmt1 in Intestinal Development and Cancer
Abstract
Patterns of DNA methylation are established and maintained by DNA methyltransferases (Dnmts), which
have traditionally been subdivided into the ‘de novo’ methyltransferases, Dnmt3a and Dnmt3b, and the
‘maintenance’ methyltransferase, Dnmt1. Dnmt1 maintains DNA methylation patterns and genomic
stability in several in vitro cell systems, but its function in tissue-specific development, homeostasis, and
disease in vivo is only beginning to be investigated.
Recently, the Kaestner lab demonstrated that loss of Dnmt1 in the adult intestinal epithelium causes a
two-fold expansion of the proliferative crypt zone, indicating that Dnmt1 and DNA methylation regulate
proliferative processes in the intestine. I hypothesized that loss of Dnmt1 may impart similar effects
during intestinal development and tumorigenesis, and employed distinct Cre-loxP mouse models to ablate
Dnmt1 in progenitor cells during intestinal development and in the mature intestinal epithelium of cancerprone ApcMin/+ mice.
In the first part of my thesis, I show that loss of Dnmt1 in intervillus progenitor cells in the developing
intestine causes global hypomethylation, DNA damage, premature differentiation, and apoptosis. I
confirm this novel role for Dnmt1 during crypt development using the in vitro organoid culture system, and
illustrate a differential requirement for Dnmt1 in immature versus mature organoids. These results
demonstrate an essential role for Dnmt1 in maintaining genomic stability during intestinal development
and the establishment of intestinal crypts.
DNA methylation is thought to drive CRC progression by the repression of tumor suppressor genes via
promoter methylation. In the second part of my thesis, I utilize inducible intestinal epithelial-specific gene
ablation to determine the requirement of Dnmt1 in intestinal tumorigenesis. Surprisingly, I find that loss of
Dnmt1 in cancer-prone ApcMin/+ mice results in accelerated, not decreased, intestinal tumor
development. Dnmt1 deletion precipitates an acute response in mature intestinal epithelium
characterized by hypomethylation of repetitive elements, genomic instability, and apoptosis, which is
followed by remethylation with time. This recovery is entirely dependent on the activity of the de novo
methyltransferase Dnmt3b. In light of these data, the current dogma regarding the role of DNA
methylation in colon cancer needs to be revisited.
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ABSTRACT
DNMT1 IN INTESTINAL DEVELOPMENT AND CANCER
Ellen N. Elliott
Klaus H. Kaestner

Patterns of DNA methylation are established and maintained by DNA methyltransferases
(Dnmts), which have traditionally been subdivided into the ‘de novo’ methyltransferases, Dnmt3a
and Dnmt3b, and the ‘maintenance’ methyltransferase, Dnmt1. Dnmt1 maintains DNA
methylation patterns and genomic stability in several in vitro cell systems, but its function in
tissue-specific development, homeostasis, and disease in vivo is only beginning to be
investigated.
Recently, the Kaestner lab demonstrated that loss of Dnmt1 in the adult intestinal
epithelium causes a two-fold expansion of the proliferative crypt zone, indicating that Dnmt1 and
DNA methylation regulate proliferative processes in the intestine. I hypothesized that loss of
Dnmt1 may impart similar effects during intestinal development and tumorigenesis, and employed
distinct Cre-loxP mouse models to ablate Dnmt1 in progenitor cells during intestinal development
and in the mature intestinal epithelium of cancer-prone Apc

Min/+

mice.

In the first part of my thesis, I show that loss of Dnmt1 in intervillus progenitor cells in the
developing intestine causes global hypomethylation, DNA damage, premature differentiation, and
apoptosis. I confirm this novel role for Dnmt1 during crypt development using the in vitro organoid
culture system,	
   and illustrate a differential requirement for Dnmt1 in immature versus mature
organoids. These results demonstrate an essential role for Dnmt1 in maintaining genomic stability
during intestinal development and the establishment of intestinal crypts.
DNA methylation is thought to drive CRC progression by the repression of tumor
suppressor genes via promoter methylation. In the second part of my thesis, I utilize inducible
intestinal epithelial-specific gene ablation to determine the requirement of Dnmt1 in intestinal
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tumorigenesis. Surprisingly, I find that loss of Dnmt1 in cancer-prone Apc

Min/+

mice results in

accelerated, not decreased, intestinal tumor development. Dnmt1 deletion precipitates an acute
response in mature intestinal epithelium characterized by hypomethylation of repetitive elements,
genomic instability, and apoptosis, which is followed by remethylation with time. This recovery is
entirely dependent on the activity of the de novo methyltransferase Dnmt3b. In light of these data,
the current dogma regarding the role of DNA methylation in colon cancer needs to be revisited.
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Introduction
Waddington coined the term “epigenetics” in 1942 to describe the burgeoning field of
developmental biology, and the mechanisms underlying development from the undifferentiated
embryo to the mature adult organism (Waddington 1942). In the modern context, epigenetics is
defined as mitotically heritable phenotypes that are mediated by mechanisms other than
alteration of DNA sequences (Berger, Kouzarides et al. 2009). These mechanisms affect
chromatin organization, i.e. the three-dimensional structure of DNA within the nucleus, which in
turn influences gene expression patterns and resulting phenotypic traits among distinct cell types.
Epigenetic modifications are classified into three general categories: DNA methylation,
histone modifications, and nucleosome positioning. Although the term “epigenetic” refers to the
inheritance of the mark through at least one mitotic cycle, all of the described epigenetic
modifications are dynamic to some extent (Berger 2007). We know that DNA methylation patterns
are first erased and then re-established during early embryonic development, and we understand
the molecular mechanism of their trans-mitotic inheritance. In contrast, the processes underlying
the maintenance of histone modifications and nucleosome arrangements through the cell cycle
are not well understood. In these instances, the marks are termed “epigenetic” due to their
capabilities to alter gene expression patterns, which are maintained in specific cell lineages.

Histone modifications and nucleosome positioning
Histones are the core proteins that comprise nucleosomes, and form the structural basis
underlying chromatin architecture. Nucleosomes consist of 147 base pairs of DNA wrapped
around a histone octamer, which contains two copies of each core histone protein (H2A, H2B,
H3, and H4) (Luger, Mäder et al. 1997). The placement and density of nucleosomes determines
the relative accessibility of DNA to different transcription factors and enzymes, and thus can
directly impact gene expression (Jenuwein and Allis 2001).
Histone proteins can be altered by covalent posttranslational modifications to their
charged tails, which protrude from the histone and are thus accessible to various modifying
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enzymes. These modifications alter the electrostatic charge of the histone tails to induce changes
in the chromatin structure. Repressive histone modifications create a more compact chromatin
environment, while activating modifications allow DNA binding factors and other proteins to
interact with DNA and increase gene expression (Kouzarides 2007). In addition, specific histone
modifications allow binding of ‘reader’ proteins, which can transmit the charged histone state into
altered gene actions. There are many types of histone modifications and corresponding enzymes.
For the purpose of this review, we have chosen the most commonly profiled modifications
described in the current literature.

Activating histone modifications
There are multiple histone modifications that distinguish active areas of chromatin, but
the most commonly found at actively transcribed genes are tri-methylation of H3K4 (H3K4me3) at
their transcription start sites (Kim, Barrera et al. 2005), and H3K36 (H3K36me3) within gene
bodies (Barski, Cuddapah et al. 2007). The H3K4me3 mark is established by SET-domain
proteins, including the well-characterized MLL protein (Krivtsov and Armstrong 2007). MLL is a
mammalian homologue of the Drosophila Trithorax complex, and is a target for translocations in
acute myeloid leukemia (Thirman, Gill et al. 1993, Krivtsov and Armstrong 2007). MLL contains a
SET domain responsible for methylation of H3K4 to the mono-, di-, and trimethylated state
(H3K4me1, me2, me3), and associates with the WDR5, RBPB5, and ASH2L proteins, which are
necessary for MLL targeting and function (Krivtsov and Armstrong 2007). H3K36me3 marks
exons within actively transcribed genes, and specifically functions to prevent aberrant RNA
polymerase activity within active genes (Venkatesh, Smolle et al. 2012). In addition, the
H3K36me3 intergenic mark contributes to DNA mismatch repair (Li, Mao et al. 2013) and
alternative splicing (Luco, Pan et al. 2010).
Enhancers are distal cis-regulatory elements that can be bound by sequence-specific
DNA-binding transcription factors to activate a given target gene, and are also associated with
multiple histone modifications. Active enhancers are characterized by H3K27 acetylation

	
  

	
  

3	
  

(H3K27Ac) (Creyghton, Cheng et al. 2010), which is established by both the CREB binding
protein (CBP) and p300 acetyltransferases (Tie, Banerjee et al. 2009). H3K4me1and H3K4me2
also mark cis-regulatory elements such as enhancers and promoters, but do not necessarily
denote active transcription (Ong and Corces 2011). Interestingly, enhancers are also frequently
sites of reduced DNA methylation (Lister, Pelizzola et al. 2009, Stadler, Murr et al. 2011, Ziller,
Gu et al. 2013, Sheaffer, Kim et al. 2014), indicative of cross-talk between histone modifications
and DNA methylation machinery (see below).

Repressive histone modifications
The two most commonly profiled repressive histone methylation marks are H3K27me3
and H3K9me3. H3K27me3 is established by the Polycomb repressive complex 2 (PRC2),
comprised of the catalytic subunits EZH1 and EZH2, in addition to core subunits SUZ12, EED
and RBBP7/4 (Margueron and Reinberg 2011). H3K27me3 is regarded as a stable histone
modification (Zee, Levin et al. 2010), and is widely distributed in ES cell chromatin (Peters,
Kubicek et al. 2003). PRC2 and H3K27me3 are responsible for silencing key lineage-specific
regulators in mouse ES cells to repress differentiation processes and maintain pluripotency
(Boyer, Plath et al. 2006). Depletion of EZH2 and EED in mouse ES cells impairs mesendoderm
differentiation (Shen, Liu et al. 2008), and deletion of SUZ12, EZH2, or EE causes severe
gastrulation defects during embryogenesis (Faust, Schumacher et al. 1995, O'Carroll, Erhardt et
al. 2001, Pasini, Bracken et al. 2007), demonstrating the critical function of PRC2 in
developmental and differentiation processes.
The H3K9me3 mark is considered a hallmark of constitutive heterochromatin and is
regulated by the SUV39H family of methyltransferases, including G9a, SUV39H1/2, and
SETDB1/2. SUV39H1/2 establish the H3K9me3 mark in heterochromatin (Peters, Kubicek et al.
2003), where its interaction with heterochromatin protein 1 (HP1) recruits additional SUV39H1/2
methyltransferases to promote gene silencing (Margueron and Reinberg 2010). SETDB1 is highly
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expressed in ES cells, and is required to maintain pluripotency and self-renewal capabilities in
vitro (Bilodeau, Kagey et al. 2009).

Nucleosome Positioning
Nucleosome remodeling complexes can completely alter the three-dimensional structure
of chromatin by the addition, subtraction, or remodeling of nucleosome subunits. These dynamic
activities are regulated by four families of proteins: SWI/SNF, ISWI, CHD, and INO80 (Portela
and Esteller 2010). These families of proteins assemble into large complexes, allowing them to
alter nucleosome position within the larger context of histone modifications and DNA methylation
patterns. All four types of complexes interact with multiple proteins, including nucleosomes,
specific histone modifications, chromatin remodeling enzymes, and transcription factors. In
addition, these remodelers all contain a catalytic subunit with a DNA-dependent ATPase domain,
which uses the energy from ATP hydrolysis to remodel nucleosomes (Portela and Esteller 2010).
The ATPases BRM and BRG1 are members of the SWI/SNF family, and share sequence
homology with the Drosophila Trithorax genes (Schuettengruber, Martinez et al. 2011). BRM and
BRG1 form multi-protein BAF remodeling complexes, which show a surprising amount of tissue
and cell-type specificity via differential inclusion of BAF protein subunits (Lessard and Crabtree
2010). Neural progenitors require BAF45a/53a subunits to support proliferation, while
differentiation to postmitotic neurons necessitates BAF45b/45c/53b (Lessard, Wu et al. 2007).
The SWI/SNF family is widely known as a master regulator of gene expression, having roles in
various pathways related to cell adhesion, alternative splicing, cell cycle regulation and
differentiation (Reisman, Glaros et al. 2009). Several members, including BRG1 and SNF5, are
frequently mutated or silenced in various types of cancers, pointing to a possible function as a
tumor suppressor (Clapier and Cairns 2009).
The CHD family of nucleosome remodelers is defined by ATPase proteins with
chromodomains, which bind methylated lysine residues in histone tails (Lessard, Wu et al. 2007).
CHD3/4 ATPases are essential for nucleosome remodeling activity in the Mi-2/NuRD complex.
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Mi-2/NuRD also contains the MBD3 protein, which binds methylated DNA, and histone
deacetylases HDAC1 and HDAC2, which deacetylate histones and tighten local chromatin
structure (Xue, Wong et al. 1998, Wade, Gegonne et al. 1999, Zhang, Ng et al. 1999). In ES
cells, Mi-2/NuRD deacetylates H3K27 to promote PRC2-mediated transcriptional repression,
which is required for ES cell pluripotency and differentiation (Kaji, Caballero et al. 2006,
Reynolds, Salmon-Divon et al. 2012). Overall, Mi-2/NuRD regulates transcriptional activity by
coupling histone deacetylation with increased nucleosome density, which alters interactions with
other histone modifying proteins.

DNA methylation
DNA methylation refers to the covalent addition of a methyl group to a cytosine base,
referred to as 5-methylcytosine (5mC), and commonly occurs in the context of a CpG
dinucleotide. CpG dinucleotides are underrepresented in the mammalian genome due to the
spontaneous deamination of 5mC to thymine. As a result of these processes, only 1% of the
human genome consists of CpG sites as opposed to the ~4 percent expected by chance, and
approximately 60-80% of these CpG sites are methylated, depending on the cell type (Smith and
Meissner 2013). The remaining unmethylated CpGs are predominantly located in regions of
increased CpG frequency, termed CpG islands (CGIs). CGIs, as defined by Takai and Jones
(2002), are ≥ 500 base pairs in length, have a CpG observed/expected ratio ≥0.65, and have at
least 55% GC content. CGIs are generally unmethylated, and are located at 72% of annotated
promoters in the human genome (Saxonov, Berg et al. 2006). Interestingly, regions of low CpG
methylation can also be found for distal CGIs in enhancers (Lister, Pelizzola et al. 2009, Stadler,
Murr et al. 2011, Ziller, Gu et al. 2013).
The enzymes that establish DNA methylation patterns are DNA methyltransferases
(DNMT). There are three DNMTs encoded in the mammalian genome, divided into two categories
based on their sequence similarities and DNA methyltransferase activities in vitro. The “de novo”
methyltransferases, DNMT3A and DNMT3B, have low affinity for hemi-methylated compared to
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unmethylated DNA in vitro (Okano, Xie et al. 1998), and can establish novel patterns of DNA
methylation. The second type of DNMT is the “maintenance” methyltransferase DNMT1. DNMT1
associates with factors at the replication fork to copy patterns of methylation onto newly
synthesized strands of DNA, thereby faithfully maintaining the pattern of DNA methylation across
multiple cell divisions (Leonhardt, Page et al. 1992). It has recently been suggested that the
categories of “maintenance” and “de-novo” are too simplistic to describe the complex interplay of
DNMT activity in vivo (Jones and Liang 2009). For example, deletion of Dnmt1 in mouse ES cells
causes only a 66% decrease in DNA methylation levels (Li, Bestor et al. 1992), suggesting that
DNMT3A and DNMT3B have some maintenance methyltransferase activity.
DNA methylation and therefore DNMTs are crucial for mammalian development. Dnmt1or Dnmt3b-null mouse embryos arrest at E.9.5, and Dnmt3a-null newborn mice are runted and
die within the first two weeks of life (Li, Bestor et al. 1992, Okano, Bell et al. 1999). Intriguingly,
triple Dnmt-knockout (TKO) mouse ES cells have normal morphology and survival in vitro, but
undergo apoptosis when induced to differentiate (Jackson, Krassowska et al. 2004, Tsumura,
Hayakawa et al. 2006). In contrast, recent studies have shown that human ES cells require
DNMT1 even during maintenance culture (Liao, Karnik et al. 2015). These results support the
notion that mouse and human ES cells denote distinct pluripotent states, with human ES cells
representing a later stage of epiblast development relative to mouse ES cells (Nichols and Smith
2009). Overall, these data strongly implicate a critical role for DNA methylation in early embryonic
development and differentiation processes.
Differential methylation patterns distinguish specific tissue and cells types, with
differential methylation occurring at CGI shores and enhancer elements (Irizarry, Ladd-Acosta et
al. 2009, Stadler, Murr et al. 2011, Ziller, Gu et al. 2013). DNA methylation acts primarily as a
repressive epigenetic modification in chromatin, downregulating expression of genes associated
with regions of increased DNA methylation. There are two broad means by which DNA
methylation can repress gene expression: direct inhibition of DNA binding transcription factors,
and interactions with other chromatin remodeling enzymes to promote a repressive chromatin
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environment. Although several examples of direct inhibition of transcription factor binding to
methylated DNA are known, including for CREB, AP-2, and E2F (Tate and Bird 1993), the
majority of studies have focused on how DNA methylation patterns influence global chromatin
organization. The effects of DNA methylation on chromatin may be indirect, such as through the
methyl CpG binding proteins MeCP2, MBD2, or MBD3. MeCP2 recruits histone deacetylases to
methylated DNA, which promotes heterochromatin formation and stable gene repression (Jones,
Veenstra et al. 1998, Nan, Ng et al. 1998). Additionally, the DNMTs directly interact with several
chromatin-remodeling complexes, such as Polycomb group protein EZH2, to facilitate
heterochromatin formation (Viré, Brenner et al. 2006).
Histone modifications, such as the repressive H3K9me, can be recognized by DNMTs to
influence heterochromatin formation and nucleosome remodeling. G9a dimethylates H3K9, which
creates a binding site for heterochromatin protein 1 (HP1). HP1 then recruits DNMT1, which
methylates CpGs to support permanent transcriptional repression (Estève, Chin et al. 2006,
Smallwood, Estève et al. 2007). Interestingly, binding to DNMT1 also stabilizes localization of
HP1, allowing HP1 to recruit other chromatin remodeling complexes to form highly structured
heterochromatin (Estève, Chin et al. 2006, Smallwood, Estève et al. 2007). In cancer, both HP1
and DNA methylation levels are globally reduced, signifying the importance of epigenetic cross
talk in disease progression (Feinberg and Vogelstein 1983, Gama-Sosa, Slagel et al. 1983,
Dialynas, Vitalini et al. 2008).
DNA methylation has long been considered the most “stable” of the epigenetic
modifications. The earliest studies of DNA methylation and DNMT function described the
processes of imprinting and X-chromosome inactivation during development (Holliday and Pugh
1975, Venolia and Gartler 1983, Bartolomei, Zemel et al. 1991). Imprinting refers to the
phenomenon of monoallelic gene expression in a parent-of-origin specific manner. One of the
best-understood examples of imprinting occurs at the H19/IGF2 locus, in which differential
methylation at the imprinting control region (ICR) located between the two genes determines
monoallelic H19 and IGF2 expression. The ICR is methylated on the paternal allele, which results
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in IGF2 expression from the paternal chromosome and H19 expression from the maternal
chromosome (Li, Beard et al. 1993). Imprints are maintained in all mature somatic cells types,
and are only erased during primordial germ cell development in embryogenesis (Plasschaert and
Bartolomei 2014).

The mammalian intestinal epithelium
One of the aims of epigenetic research is to elucidate how the various marks interact with
one another, and which components are essential to disease progression and prevention. To
study chromatin dynamics in vivo, during development as well as homeostasis and disease
progression, requires a model system that closely parallels its human counterpart but is still
genetically tractable. The mouse intestinal epithelium fits these requirements, and is an excellent
model for the study of chromatin in modulating gene expression and disease. The structural
components of the mouse intestinal epithelium are strikingly similar to those of the human
intestine. Models for human intestinal disease, including colorectal cancer and inflammatory bowl
disease, are well established in the mouse, which permits studies of chromatin marks and
complexes in disease progression. The precise mechanisms that regulate intestinal epithelial
homeostasis and disease have remained elusive, and it is possible that epigenetic marks play a
crucial role in such processes.
The adult intestinal epithelium consists of a single layer of columnar cells lining the lumen
of the intestine. The epithelium is structured into crypts that invaginate into the underlying
mesenchyme, and villi that project into the intestinal lumen (Figure 1.1). In intestinal homeostasis,
the crypt-based columnar (CBC) stem cells give rise to rapidly dividing transit-amplifying crypt
cells. As the transit amplifying cells exit the crypt, they differentiate into one of five major cell
types: absorptive cells, called enterocytes, goblet cells, enteroendocrine cells, Paneth cells
(Cheng and Leblond 1974), and Tuft cells (Gerbe, Legraverend et al. 2012). Paneth cells are
retained at the base of the crypt, while the other types of differentiated cells migrate up the villi.
Differentiated cells migrate in ordered cohorts along the villi as more cells are produced, and
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reach the top of the villus after 3-5 days, at which point the cells apoptose and are shed into the
intestinal lumen. This high rate of cellular turnover indicates tight regulation of cell proliferation
and differentiation processes. Indeed, misregulation of intestinal crypt proliferation is the hallmark
of intestinal and colorectal cancer (Fearon 2011).

The intestinal stem cell niche and Wnt signaling
Crypts form the intestinal stem cell niche, and harbor two well-characterized populations
of stem cells (Figure 1.1). The first are the crypt-based-columnar (CBC) stem cells, which express
the markers Lgr5 and Olfm4, and give rise to all cell types in the intestinal epithelium (Barker, van
Es et al. 2007, van der Flier, Haegebarth et al. 2009). CBCs are considered the active population
of intestinal stem cells, and divide approximately once every 24 hours. The second population of
stem cells are the quiescent “+4 stem cells,” marked by Bmi1, Tert, and Hopx (Barker, van
Oudenaarden et al. 2012). The +4 stem cells constitute a reserve population; upon ablation of the
CBC population in mice, +4 stem cells can give rise to new CBC stem cells and repopulate the
intestinal epithelium (Tian, Biehs et al. 2011). In separate studies, it was also shown that the CBC
cells can give rise to +4 stem cells (Takeda, Jain et al. 2011). As a result, it is difficult to make a
clear distinction between the two interconverting stem cell populations. It is possible that the crypt
base contains a equipotent population of intestinal stem cells, and that the cell position within the
crypt determines whether the cell is a fast- or slow-dividing stem cell. Evidence supporting this
+

equipotent stem cell hypothesis comes from studies of irradiated mice, in which Dll1 secretory
+

precursors can convert to Lgr5 CBCs to compensate for epithelial loss (van Es, Sato et al.
2012).
The main signaling pathway that supports proliferation in the crypt, both in vivo and in
vitro, is the canonical Wnt signaling pathway. Briefly, canonical Wnt signaling depends on
cytoplasmic stabilization of β-catenin, via disassociation of the Gsk3β-APC-Axin destruction
complex. Accumulation of stable β-catenin protein in the cytoplasm results in its translocation to
the nucleus, where it interacts with Tcf/Lef DNA binding effector proteins at target genes to
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activate transcription. Wnt activity is required to maintain proliferation in the adult intestinal crypt;
overexpression of the secreted Wnt antagonist Dkk1 in mouse intestinal epithelium inhibits
proliferation, and blocks formation and maintenance of crypts (Pinto, Gregorieff et al. 2003,
Kuhnert, Davis et al. 2004). Deletion of Tcf4, the main β-catenin nuclear effector in mouse
intestinal epithelium, causes complete loss of proliferation and stem cell identity in the adult
intestine, and mice die ~9 days following ablation (Korinek, Barker et al. 1998).
Paneth cells are proposed to have an active role in maintaining the CBC stem cells
through their secretion of Wnt ligands (Sato, van Es et al. 2011). This hypothesis was supported
+

by observations that single Lgr5 cells grow more efficiently in vitro when paired with a Paneth
cell (Sato, van Es et al. 2011). However, ablation of Paneth cells has no deleterious effects on
CBC homeostasis or crypt architecture in adult mice (Durand, Donahue et al. 2012), suggesting
there are redundant mechanisms to maintain proliferation and Wnt signaling in vivo. Inhibiting
Wnt ligand secretion concurrently in Paneth cells and subepithelial myofibroblasts did not alter
crypt proliferation or crypt-villus architecture in adult mice (San Roman, Jayewickreme et al.
2014). However, there is some evidence that supports a critical role for the mesenchyme in
maintaining the intestinal stem cell niche. Kabiri and colleagues inhibited epithelial Wnt secretion,
and demonstrated that epithelial Wnt ligands are not required for crypt maintenance during
development, homeostasis, or following injury (2014). Interestingly, ex vivo organoid cultures from
these mice illustrated a dependence on exogenous Wnt sources. The authors reported that coculture with wild-type intestinal stromal cells negated the requirement for supplementation with
Wnt factors, strongly suggesting that the niche supporting cells exist within the intestinal stroma
(Kabiri, Greicius et al. 2014). Thus, there are many populations of distinct mesenchymal cells
surrounding the intestinal epithelium, and it is likely that one of these cell types is supporting the
intestinal crypt.
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Differentiation in the intestinal epithelium
There are five main types of differentiated cells in the intestinal epithelium: absorptive
enterocytes, goblet cells, Paneth cells, enteroendocrine cells, and Tuft cells (Figure 1.1).
Although enterocytes comprise ~90% of the intestinal villi cell population (Cheng and Leblond
1974), the other types of differentiated cells secrete proteins that are crucial to intestinal function
and survival. Goblet cells secrete mucin, the main component of mucus and the intestinal
epithelial barrier, and are important to protect against potential pathogens in the lumen. Mucus
coats the entire intestinal epithelium, acting as a lubricant to promote digestion, and preserves
the structure of the epithelium upon physical force or injury (van der Flier and Clevers 2009).
Enteroendocrine cells secret various hormones, including glucagon-like peptides 1 and 2 (GLP-1,
-2), cholecystokinin (CCK), Glucose-dependent insulinotropic peptide (GIP), and somatostatin
(SST) (Lee and Kaestner 2004). There are ~15 types of enteroendocrine cells, and their secreted
hormones have important functions in feeding behavior, satiation, and glucose homeostasis
(Cummings and Overduin 2007). For instance, GLP-1 is released in the small intestine following
food intake, and promotes glucose uptake by stimulating pancreatic β-cell insulin secretion
(Kreymann, Williams et al. 1987, Mojsov, Weir et al. 1987).
Paneth cells are distinct from the other types of differentiated cells. As they differentiate
from the transit-amplifying pool, they migrate to the base of the crypt and reside interspersed
between the CBC stem cells (Figure 1.1). Paneth cells are long-lived relative to villus cell
populations, surviving for approximately one month in the crypt epithelium (Troughton and Trier
1969). Their main function is to secrete lysozyme and other defensin proteins that protect against
bacterial infection in the epithelium (Porter, Bevins et al. 2002).
Another type of endocrine cell, the Tuft cell, comprises 0.4% of the intestinal epithelium
(Gerbe, Legraverend et al. 2012) and has garnered much attention over the past five years due to
the discovery of their distinct cell lineage. Although they require the pan-endocrine transcription
factor Atoh1 for differentiation, Tuft cells do not require the other factors necessary for
enteroendocrine, goblet, or Paneth cell specification (Gerbe, van Es et al. 2011). Tuft cells are
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marked by expression of Dclk1, and have been shown to contribute to intestinal recovery
following injury (Gerbe, Brulin et al. 2009, Westphalen, Asfaha et al. 2014). Dclk1 is also a
+

putative cancer stem cell marker, and loss of Dclk1 cells abrogates tumorigenesis on the Apc

Min/+

colorectal cancer mouse model (May, Riehl et al. 2008, Nakanishi, Seno et al. 2013).

Notch signaling regulates differentiation and stem cells
Notch is one of the most important signaling pathways in the intestinal epithelium, and
has crucial roles in regulating both intestinal proliferation and differentiation processes. The Notch
signaling pathway works via lateral inhibition, in which one cell expressing the Delta ligand
activates the Notch receptor on an adjacent cell. Activation of the Notch receptor causes
cleavage of its intracellular domain, which subsequently translocates to the nucleus and forms a
complex with the DNA-binding transcription factor CSL (CBF-1/RBP-Jκ, Su(H), Lag-1). CSL
normally acts to repress gene expression, but binding of the Notch intracellular domain (NICD)
converts CSL to a transcriptional activator. In the intestinal epithelium, secretory precursors
expressing the Delta ligand (Dll) activate Notch signaling in neighboring cells. NICD activity
increases expression of the bHLH transcription factor Hes1, which supports enterocyte
differentiation via its repression of Atoh1 (Jensen, Pedersen et al. 2000, Zheng, Tsuchiya et al.
2011). Atoh1 is a bHLH transcription factor necessary (Yang, Bermingham et al. 2001, Shroyer,
Helmrath et al. 2007) and sufficient (VanDussen and Samuelson 2010) for all secretory lineages
in the intestinal epithelium. Notch signaling opposes Atoh1 activation to direct cell fate into the
enterocyte lineage. Loss of Notch signaling causes increased secretory cell differentiation along
the crypt-villus axis, either through use of γ-secretase inhibitors (van Es, van Gijn et al. 2005,
VanDussen, Carulli et al. 2012), or by ablation of Notch receptors (Riccio, van Gijn et al. 2008,
Carulli, Keeley et al. 2015), Dll ligands (Pellegrinet, Rodilla et al. 2011), or CSL/RBP-Jκ (van Es,
van Gijn et al. 2005). Combined loss of Notch signaling and Atoh1 expression blocks secretory
cell fate conversion and induces global enterocyte differentiation (Kazanjian, Noah et al. 2010,
van Es, de Geest et al. 2010, Kim and Shivdasani 2011, VanDussen, Carulli et al. 2012),
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establishing that Notch acts specifically through that Atoh1 to regulate secretory cell fate, and that
active Notch is not required for enterocyte differentiation. Conversely, mice with forced overexpression of Notch ICD display severe reduction of secretory cell types and increased
enterocyte differentiation (Fre, Huyghe et al. 2005, Stanger, Datar et al. 2005).
Interestingly, over-expression of the NICD causes increased crypt cell proliferation (Fre,
Huyghe et al. 2005, Stanger, Datar et al. 2005), whereas loss of Notch signaling blocks
proliferation and converts crypt cells to secretory cell fates (van Es, van Gijn et al. 2005, Riccio,
van Gijn et al. 2008, Pellegrinet, Rodilla et al. 2011, VanDussen, Carulli et al. 2012). Notch
pathway inhibition decreases expression of CBC stem cell marker genes, including Olfm4 and
Lgr5 (Pellegrinet, Rodilla et al. 2011, VanDussen, Carulli et al. 2012, Carulli, Keeley et al. 2015).
VanDussen and colleagues found that the NICD directly activates expression of Olfm4,
demonstrating the crucial function of Notch signaling in maintaining the CBC stem cell population
(2012).
Notch signaling components are expressed in the crypt, and interact with Wnt signaling to
support stem cell renewal, proliferation, and differentiation processes (Noah and Shroyer 2013).
In fact, Wnt activation strongly favors a secretory cell fate by its positive regulation of Atoh1 and
Sox9 (Pinto, Gregorieff et al. 2003, Blache, van de Wetering et al. 2004), important for Paneth
cell fate, and mouse models with decreased Wnt signaling display reduced numbers of secretory
cells (Korinek, Barker et al. 1998, Pinto, Gregorieff et al. 2003). Activation of Notch in the Tcf4null, non-proliferative developing intestinal epithelium fails to restore progenitor cell division (Fre,
Pallavi et al. 2009). A recent report from Tian et al. (2015) used Notch-inhibiting antibodies to
illustrate that Notch inhibition allows increased Wnt-activation of secretory genes, such as
lysozyme, at the expense of crypt cell proliferation. Concurrent treatment with both Wnt- and
Notch-blocking antibodies restored CBC proliferation and normal cell differentiation, suggesting
that Notch mediates its effects in part through Wnt pathway inhibition (Tian, Biehs et al. 2015).
These experiments demonstrate that cooperation between Notch and Wnt signaling is crucial to
maintain proliferation and differentiation processes in the intestinal epithelium.
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Crypt-villus organization: Hedgehog and BMP
The architecture of the intestinal epithelium is tightly regulated, and misregulation of
crypt-villus organization is a step in disease progression. There are several signaling pathways
essential for maintaining the crypt-villus axis demarcation. Many of these signals are active during
intestinal development, and require cross talk between the intestinal epithelium and the
surrounding mesenchymal tissue.
The Hedgehog ligands Sonic hedgehog (Shh) and Indian hedgehog (Ihh) are expressed
in developing epithelium, and become restricted to proliferative regions as development
progresses (Ramalho-Santos, Melton et al. 2000). The Hedgehog receptors, Patched, and their
effectors, the Gli transcription factors, are expressed in the underlying mesenchyme (RamalhoSantos, Melton et al. 2000). Hedgehog signaling during intestinal development becomes active
upon binding of epithelial Hh ligands to Patched receptors expressed in intestinal mesenchyme.
Hedgehog (Hh) ligand binding to Patched relieves inhibition of Smoothened, which activates Gli
transcription factors; Gli then translocates to the nucleus, where it regulates expression of Hh
target genes. Expression of the pan-Hh inhibitor Hhip in the developing intestinal epithelium
impairs villus morphogenesis and increases Wnt signaling, resulting in flattened hyperproliferative intestinal epithelium (Madison, Braunstein et al. 2005).
The Hhip-mice also display disorganization of myofibroblasts normally associated with
crypt epithelium, and significantly decreased BMP ligand expression within the intestinal
mesenchyme (Madison, Braunstein et al. 2005). Similar to Hedgehog, BMP signaling also
requires crosstalk between the mesenchyme and epithelium. In this situation, however, the BMP
ligands are expressed in the mesenchyme, and the receptors are expressed in the epithelium
(Haramis, Begthel et al. 2004). During intestinal development, the BMP ligands are expressed in
clusters of mesenchymal cells underlying putative villi (Karlsson, Lindahl et al. 2000), and the
highest levels of BMP signaling are observed in villi (Madison, Braunstein et al. 2005). When the
BMP antagonist Noggin is overexpressed in intestinal epithelium (Haramis, Begthel et al. 2004,
Batts, Polk et al. 2006), or if the BMP receptor is ablated (He, Zhang et al. 2004), irregular hyper-
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proliferative crypt structures appear throughout the epithelium, confirming a role for BMP in
supporting villus formation and repressing crypt development. It has been posited that epithelial
Hedgehog signals promote mesenchymal BMP activation, and that both pathways antagonize
one another to ensure proper crypt and villus formation (Roberts, Johnson et al. 1995, Roberts,
Smith et al. 1998, Sukegawa, Narita et al. 2000, Ishizuya-Oka, Hasebe et al. 2006). However,
direct activation of BMP signaling by Hedgehog has not been demonstrated in the mammalian
intestinal epithelium in vivo.
The Foxl1 transcription factor is highly expressed in intestinal mesenchyme (Kaestner,
Bleckmann et al. 1996), and regulates the transition from pseudostratified to columnar epithelium
during intestinal epithelial development. Ablation of Foxl1 results in delayed crypt-villus
morphogenesis, and abnormal proliferation patterns in late fetal stages and the first two weeks of
life (Kaestner, Silberg et al. 1997). Foxl1 is also a bona-fide Hedgehog target gene, and contains
several highly conserved Gli binding sites near its promoter (Madison, McKenna et al. 2009).
Interestingly, BMP ligand expression is decreased in developing Foxl1-mutant intestinal
mesenchyme (Kaestner, Silberg et al. 1997), suggesting that Foxl1 may be the link modulating
BMP and Hedgehog signals between epithelial and mesenchymal cells (Madison, McKenna et al.
2009).

Transcriptional and Epigenetic Regulation of the Intestinal Epithelium
The genetics of key DNA binding transcription factors in the intestinal epithelium has
been extensively studied, but less is known about the role of chromatin marks and mediators in
the processes of intestinal homeostasis. Two conflicting viewpoints have emerged over the past
decade (Figure 1.2). The first is the concept that the chromatin of the intestinal epithelium is
largely permissive, and that transcription factor activity is the defining characteristic that alters
gene expression patterns (Figure 1.2 A-B). The second posits that the chromatin itself plays an
important role in regulating gene expression, and that chromatin states are not necessarily
dependent on transcription factor activity (Figure 1.2 C-D).
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Transcription factors regulate open chromatin and intestinal homeostasis
There are several transcription factors that are globally important for intestinal epithelial
development, maintenance, and proliferation. Cdx2 is master-regulator of intestinal epithelial
differentiation, and is essential for the specification of all intestinal epithelia during mouse
endoderm development (Gao, White et al. 2009). Cdx2 ablation in mouse endoderm prevents
colon and rectum morphogenesis and causes global defects in differentiation and proliferation
transcriptional programs (Gao, White et al. 2009). Cdx2 is also required for normal activation of
pro-intestine transcription factors, including Hnf1α, Hnf4 α, and Cdx1, and regulates Hedgehog
ligand secretion from the epithelium to the underlying mesenchyme (Gao, White et al. 2009).
Loss of Cdx2 at mid-gestation perturbs apical-basolateral polarity of the developing epithelium,
causing deficient enterocyte development and maintenance (Gao and Kaestner 2010). In
addition, inducible deletion of Cdx2 in the adult gut reduces villus length and the numbers of
enterocytes, causing nutrient malabsorption and death within three weeks (Verzi, Shin et al.
2010, Verzi, Shin et al. 2011). Each of these studies demonstrated that Cdx2 is capable of both
transcriptional repression and activation, based on gene expression changes following Cdx2 loss
(Gao, White et al. 2009, Gao and Kaestner 2010, Verzi, Shin et al. 2011).
To study the CDX2 binding dynamics during intestinal cell differentiation, Verzi and
colleagues first utilized the Caco-2 human cell line, which can be manipulated to produce
homogeneous populations of proliferative and differentiated intestinal cells. They performed
H3K4me2, H3K27ac, and CDX2 ChIP-Seq to demonstrate that CDX2 binds distinct cis-regulatory
sites in differentiated and proliferative cell states (Figure 1.2 A-B) (Verzi, Shin et al. 2010). In the
same model system, they showed that CXD2 preferentially co-localizes with GATA6 at enhancermarked chromatin in proliferative cells, and HNF4α at different enhancer elements in
differentiated cell populations (Figure 1.2 B) (Verzi, Shin et al. 2010). In differentiated mouse villi,
Verzi and colleagues found that Cdx2 co-localized with Hnf4α at many distal enhancer elements,
which they defined as 450-600 bp regions flanked by H3K4me2-marked nucleosomes (Figure 1.2
B) (2013). Loss of Cdx2 in mouse intestinal villi reduced HNF4α binding at co-bound sites (Verzi,
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Shin et al. 2013), in agreement with previous data showing that Cdx2 regulates Hnf4α expression
(Gao, White et al. 2009). Interestingly, they also discovered that Cdx2-bound sites displayed
reduced H3K4me2 nucleosome occupancy in Cdx2-deficient villi, and conclude that Cdx2 is
required to maintain open chromatin in differentiated cells (Verzi, Shin et al. 2010, Verzi, Shin et
al. 2013). These findings build upon previous work that established Cdx2 as the master-regulator
of intestinal epithelial differentiation (Gao, White et al. 2009, Gao and Kaestner 2010), and
suggest that Cdx2 exerts this function both by its ability to control chromatin compaction and
through its interactions with multiple transcription factors.
Based on the above data, it appears that Cdx2 maintains the intestinal epithelium in a
largely active chromatin state (Figure 1.2 A-B). These conclusions are supported by additional
studies that more thoroughly analyzed histone marks during in vivo differentiation. Through
advanced genetic and cell sorting techniques it is possible to isolated various populations of cells
from the adult mouse intestine, including the Lgr5

+

stem cells, secretory progenitors, and

enterocyte progenitors. Kim and colleagues performed H3K4me2 and H3K27ac ChIP-Seq,
DNAseI mapping, and RNA-Seq to define the different cell populations by their open chromatin
states and associated gene expression (2014). Although the stem cells, secretory progenitors,
and enterocytes display distinct transcript profiles, the enterocyte and secretory progenitor
populations have remarkably similar H3K27ac, H3K4me2, and DNAseI profiles, which indicate
active enhancer elements and globally open chromatin structure (Kim, Li et al. 2014). The authors
propose that DNA-binding factors influence chromatin activity during the differentiation process,
and that the labile chromatin structure renders progenitors capable of reacting to the available set
of transcription factors. To test this hypothesis, they attempted to direct progenitor cell fate in vivo
by genetic manipulation of lineage-specific transcription programs. Acute inhibition of Notch
signaling forces progenitors to adopt a secretory cell fate within two days. Following global
conversion of progenitors to secretory cell fate, the authors induced loss of Atoh1, which is
completely required for secretory lineages. As the authors predicted, secretory progenitors
present at the outset of Atoh1 deletion convert to enterocyte fates (Kim, Li et al. 2014). They

	
  

	
  

18	
  

concluded that the dynamic abilities of progenitor cells to convert lineages is due to their similar
chromatin profiles, and that expression of distinct transcription factors specifies cell fate.
Additional work has characterized the function of the H3K79 methyltransferase DOT1L in
the mouse intestinal epithelium. H3K79me2 is associated with both heterochromatin and
euchromatin in model organisms and has known functions in transcriptional elongation, cell cycle
checkpoints, and DNA repair (Nguyen and Zhang 2011). DOT1L-mediated gene activation is
commonly employed in human leukemias with MLL translocations, making DOT1L an attractive
target in disease research (Okada, Feng et al. 2005). Two recent studies analyzed the
requirements for DOT1L and H3K79me, and reported strikingly different results.
Mahmoudi and colleagues originally identified Mllt10/Af10 in a screen for proteins that
bind directly to the Tcf4/Wnt-signaling complex in the mouse intestinal epithelium (2010).
MLLT10/AF10 directly interacts with the DOT1L methyltransferase to promote transcriptional
activation, and is the primary mechanism by which DOT1L is activated in human leukemia
(Okada, Feng et al. 2005, Nguyen and Zhang 2011). The authors report that DOT1L and the
Mllt10/Af10 mediators are essential for Wnt target activation in intestinal crypts (Mahmoudi, Boj et
al. 2010). However, these conclusions were only validated at Axin and C-myc, two canonical Wnt
target genes.
A comparable study from an independent research group also evaluated the function of
DOT1L in the intestinal epithelium, with different results (Ho, Sinha et al. 2013). They profiled
H3K79me2 and RNA expression levels in villi and crypts isolated from adult mouse intestine.
Surprisingly, the authors demonstrate similar levels of H3K79me2 at various Wnt targets in both
crypt and villus compartments. They do note that H3K79me2 generally correlates with increased
expression of associated genes, for both Wnt and non-Wnt target genes. Ablation of DOT1L in
the intestinal epithelium caused global loss of H3K79me, but did not have any deleterious effects
on differentiation or crypt-villus morphology. Indeed, Wnt targets were expressed at normal levels
in the absence of DOT1L, indicating that the H3K79me2 mark is not essential for intestinal
epithelial gene activation (Ho, Sinha et al. 2013). Ho and colleagues clearly demonstrate that
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DOT1L-mediated H3K79me2 associates with transcribed genes both in crypts and villi, and is not
required for Wnt target gene activation in intestinal crypt cells (2013).
Overall, these studies suggest that the chromatin landscape of the intestinal epithelium is
largely accessible, particularly at enhancer and regulatory elements. This enhancer chromatin is
amenable to changes induced by transcription factors, such as Cdx2 and Hnf4α, and allows
progenitor cells to quickly adapt to specific cell fates. These statements align well with reports of
plasticity within the intestinal epithelium upon tissue damage (van Es, Sato et al. 2012). However,
a comprehensive study comparing various repressive and activating histone modifications in
intestinal epithelial cell sub-populations has not been reported. In the future, it will be important to
profile multiple histone marks in the stem cell, progenitor, and differentiated cell types in order to
fully understand the function of chromatin during intestinal homeostasis and disease.

DNA methylation regulates enhancers and intestinal proliferation
The second view within the current literature introduced above is that chromatin and its
associated modifications play a significant role in regulating proliferation and differentiation in the
intestinal epithelium. This premise closely aligns with the two reports profiling genome-wide
+

methylation levels in intestinal Lgr5 CBC stem cells and differentiated villus cells. Both studies
reported similar methylomes between stem and differentiated cells, and focused their analyses
specifically on enhancer regions that have altered DNA methylation between the two cell
populations.
In the first published study, the authors note low levels of DNA methylation at the majority
of transcription start sites, which they suggest primes cells for the process of differentiation. Their
data analysis required a 40% change in DNA methylation between the two cell populations for
identification as a differentially methylated region (DMRs), resulting in the discovery of only 50
DMRs (Kaaij, van de Wetering et al. 2013). The majority of these DMRs lost DNA methylation
from stem to differentiated cell. Interestingly, these DMRs were positive for H3K4me1 and
H3K27ac enhancer marks, and several of these putative enhancers loop and make contact with
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the transcription start site of differentially expressed genes (Kaaij, van de Wetering et al. 2013).
Many DMRs were also located near Tcf4 binding sites, indicating possible regulation by Wnt
signaling. Unfortunately, the authors provided only limited in vivo data testing of their hypothesis
that loss of Tcf4 correlates with higher methylation levels at several DMRs in villi, and suggest
that Wnt signaling interacts with chromatin to promote DNA demethylation during the
differentiation process (Kaaij, van de Wetering et al. 2013).
A second study employed vastly different bioinformatics approaches, resulting in
identification of considerably more DMRs (Sheaffer, Kim et al. 2014). The authors note that
modest DNA methylation levels of 13.9-50% identify most enhancer regions (Stadler, Murr et al.
2011), and suggest that a 40% change in methylation for DMR identification is too strict a
limitation. Sheaffer and colleagues report that the average change in methylation at DMRs was
15%, and that these changes were enriched at CGIs and CGI shores (2014). These data align
with the observations that alterations in CG methylation affecting tissue and cell-specific gene
expression often occur in CGIs and shores (Irizarry, Ladd-Acosta et al. 2009, Stadler, Murr et al.
2011, Ziller, Gu et al. 2013). They performed parallel H3K27ac ChIP-Seq and RNA-Seq, and also
utilized available Cdx2 and Hnf4α ChIP-Seq data (Verzi, Shin et al. 2013)(Verzi, Shin et al.
2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al.
2013), to correlate DMRs with active enhancer elements during the differentiation process. Many
DMRs that gained methylation during differentiation associate with highly expressed ISC genes,
+

and demonstrate increased H3K27ac and Cdx2 binding in the Lgr5 population relative to villus
cells (Figure 1.2 C-D). DMRs that lost methylation from the stem to differentiated cell state
corresponded with increased expression of the associated gene, which were enriched for
metabolism and enterocyte-specific transcripts. Interestingly, they discovered that these
differentiation-DMRs also gained H3K27ac, and displayed increased Cdx2 and Hnf4α binding in
+

differentiated cells versus Lgr5 ISCs (Sheaffer, Kim et al. 2014). These data indicate that DNA
methylation works in combination with transcription factors to activate enhancers and modulate
gene expression programs during intestinal differentiation.
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The authors also employed genetic means to demonstrate that DNA methylation has
significant effects on cell proliferation and differentiation in vivo. Inducible deletion of Dnmt1 in the
adult mouse intestine caused an approximately two-fold expansion of the crypt compartment, and
increased expression of Lgr5 and Olfm4, markers of active CBC stem cells (Sheaffer, Kim et al.
2014). Targeted bisulfite sequencing upstream of these stem cell genes revealed demethylation
at putative enhancer elements, implicating a role for Dnmt1 and DNA methylation in promoting
cell differentiation and restricting crypt cell proliferation (Figure 1.2 C-D) (Sheaffer, Kim et al.
2014). The above experimental results strongly suggest a role for DNA methylation in regulating
enhancer activation and controlling processes relating to cell proliferation.

Epigenetic Modifications and Aberrations in Intestinal Disease
Colorectal cancer (CRC) is the third most common type of cancer in the United States,
with a lifetime incidence of approximately 5% in both men and women (Siegel, Desantis et al.
2014). The risk of developing colorectal cancer increases with age, as 60% of CRC diagnoses
and 70% of deaths relating to CRC occur in patients at 65 years or older (Siegel, Desantis et al.
2014).
The adenoma to carcinoma progression is well characterized in human CRC, and it may
take several decades for a malignant tumor to fully form. Cancers begin as hyper-proliferative
crypts that have accumulated mutations in tumor suppressor genes, such as APC, a Wnt inhibitor
that is mutated in 80% of sporadic CRCs (Fearon 2011). Loss of APC causes constitutive Wnt
activation and increased proliferation, resulting in dysplastic crypts. Over time, these hyperproliferative foci develop into adenomatous polyps, or adenomas. Adenomas are generally
benign, but a small percent progress to carcinoma, and adenomatous polyps are the main
precursor to invasive colorectal cancers (Jass 2007).
Development from adenoma to carcinoma requires multiple gene mutations; primary
tumors harbor up to 80 distinct somatic mutations, and as many as 7 major genetic translocations
or duplications (Wood, Parsons et al. 2007, Leary, Lin et al. 2008). Tumor suppressor proteins,
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including p53 and PTEN in addition to APC, accumulate inactivating mutations that allow
unrestrained proliferative activity. Typically, both alleles of a tumor suppressor gene must be
inactivated to cause a phenotype, following Knudson’s two-hit rule (Fearon 2011). Thus, germline
inheritance of a heterozygous allele at these genes renders patients sensitive to cancer initiation
by a loss-of-heterozygosity (LOH) mutation mechanism. Loss of tumor suppressor gene function
is important in promoting genomic instability, a key feature of most invasive carcinomas. For
instance, nearly 70% of CRCs display mutations in chromosome 18q (Vogelstein, Fearon et al.
1988). These mutations inactivate TGF-β signaling, which normally acts to restrict intestinal cell
proliferation to the crypt. Oncogenic mutations are common in CRC as well, with approximately
40% of CRCs demonstrating activating mutations at KRAS to support cell division via the EGFR
pathway (Fearon 2011).
Sporadic CRCs are separated into two general categories: those with microsatellite
instability and mismatch repair deficiencies, and those that are microsatellite stable but display
chromosomal aneuploidy and large-scale genomic alterations (Network 2012). Microsatellite
instability (MSI) refers to changes in the length of microsatellite repeat elements, and is usually
caused by defects in the DNA mismatch repair (MMR) machinery. MSI is significantly associated
with the human heredity nonpolyposis colorectal cancer (HNPCC) syndrome (Fearon 2011). The
+

gene most commonly inactivated in MSI cancers is Mlh1, although other MMR proteins including
MSH2, PMS1, and PMS2 account for a significant subset of gene mutations (Vilar and Gruber
2010). The incidence of MSI is nearly 100% in HNPCC patients, but occurs in only ~15% of
sporadic CRC (Aaltonen, Peltomäki et al. 1993).
The remaining 85% of sporadic CRCs are microsatellite stable, but show a high degree
of chromosomal instability (CIN) (Rajagopalan, Nowak et al. 2003). CIN tumors display increased
rates of aneuploidy, such as the translocations frequently cited on chromosome 18q, and high
levels of LOH at tumor suppressor genes (Fearon 2011). The CIN phenotype is considered
dominant; when CIN cells are fused with non-CIN cells, a CIN phenotype is transferred. When
two non-CIN cells are fused, the mere presence of 4 copies of each chromosome does not
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induce CIN, indicating the cancer cells harbor a specific phenotype (Lengauer, Kinzler et al.
1997). CIN tumors also associate with mutations in the genes encoding spindle-related proteins,
such as BUB1 and MAD2 (Cahill, Lengauer et al. 1998, Michel, Liberal et al. 2001). However,
there has been continued speculation that the CIN phenotype is simply an artifact of cancer
progression, and this argument will likely continue until a molecular mechanism for CIN is found
(Pino and Chung 2010).
There are also several human genetic syndromes that predispose to CRC. Familial
adenomatous polyposis (FAP) patients have germ-line APC mutations, leaving them with only
one functional copy of this crucial tumor suppressor protein (Fearon 2011). Thus, the likelihood of
loss of heterozygosity at the APC locus is dramatically increased in FAP patients, and nearly
100% of cases develop CRC by 36 years of age (Galiatsatos and Foulkes 2006). Typical
treatment for FAP involves resection of the colon in early adulthood to prevent development of
metastatic CRC (Lynch and de la Chapelle 2003). Although FAP accounts for only 0.5% of CRC
cases (Fearon 2011), its genetic basis has made it attractive for use in model organisms. The
Apc

Min/+

mouse model is based on the human FAP syndrome, and is the main model for studies of

CRC development and progression (Su, Kinzler et al. 1992). Tumors in Apc

min/+

mice are Apc-

negative, demonstrating that loss of heterozygosity (LOH) is required for tumor development
(Luongo, Moser et al. 1994). Interestingly, Apc

Min/+

mice form tumors predominantly in the small

intestine, as opposed to human FAP, which develops adenomas in the colon (Su, Kinzler et al.
1992). The cause for this different anatomical site is not well understood, although it has been
noted that several markers of human CRC, such as the CBC stem cell marker Olfm4, are not
expressed in the murine colonic epithelium (van der Flier, Haegebarth et al. 2009). Nevertheless,
Apc

Min/+

mice have proven to be a useful tool in understanding both intestinal and colorectal

tumorigenesis.
The epigenetic contribution to CRC has been studied extensively over the past thirty
years, but there is still much we do not understand about its role in carcinogenesis. The majority
of these studies focused on the function of DNA methylation, because colorectal cancers
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generally display genome-wide hypomethylation that occurs early in the adenoma-carcinoma
progression sequence (Goelz, Vogelstein et al. 1985, Feinberg, Gehrke et al. 1988). Below, we
outline the proposed function of altered epigenetics in human CRC, and the information we have
gleaned from studies of DNA methyltransferase mutations in mouse models of intestinal and
colorectal cancer.

DNA methylation patterns in human colorectal cancer
The precise function of hypomethylation in human CRC progression is not well
understood. The earliest epigenetic profiling of cancer cells noted genome-wide hypomethylation
in malignant human colorectal tumors (Feinberg and Vogelstein 1983, Gama-Sosa, Slagel et al.
1983). In later studies, it was discovered that even benign polyps and precancerous adenomas
were substantially demethylated, with a reduction of 8-10% compared to histologically normal
adjacent tissue (Goelz, Vogelstein et al. 1985, Feinberg, Gehrke et al. 1988). These results were
striking, and implicated a role for DNA methylation in colorectal tumorigenesis. Global genomic
hypomethylation may cause activation of proliferation-associated genes, and leads to increased
mutation rates based on in vitro data (Chen, Pettersson et al. 1998). Analyses of human CRC cell
lines indicates that hypomethylation causes expression of previously silenced genes (Nakamura
and Takenaga 1998), and correlated with increased genomic instability (Lengauer, Kinzler et al.
1997). Ablation of DNMT1 in a human CRC cell line caused hypomethylation, DNA replication
defects, cell cycle arrest, and apoptosis (Chen, Hevi et al. 2007).
Notably, in CRC tumor suppressor genes often display decreased expression, few
genetic alterations, and increased promoter or CGI methylation. This promoter hypermethylation
has been studied extensively, and is a defining characteristic of the CpG Island Methylator
Phenotype, or CIMP (Toyota, Ahuja et al. 1999). CIMP-high (CIMP-H) tumors display increased
DNA methylation at CGIs of tumor suppressors including CDKN2A (p16), THBS1, and Mlh1.
CIMP-H tumors account for nearly all CRCs containing oncogenic BRAF/MAPK-pathway
mutations (Weisenberger, Siegmund et al. 2006), and is also common among tumors displaying
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MSI (Issa 2004). In sporadic MSI

+

tumors, DNA mismatch repair (MMR) genes are often

inactivated via promoter hyper-methylation. The association of MSI with CGI hypermethylation at
multiple tumor suppressor genes strongly implicates CIMP as the underlying cause of genomic
instability in MSI (Weisenberger, Siegmund et al. 2006). MSI also correlates with loss of genomic
imprinting (Cui, Horon et al. 1998), and mutations at the SWI/SNF chromatin-remodeling gene
ARID1A (Jones, Li et al. 2012).
With the advent of next-generation sequencing, there have been multiple studies aiming
to profile the epigenome of human CRC (Irizarry, Ladd-Acosta et al. 2009, Berman,
Weisenberger et al. 2012, Network 2012). The Cancer Genome Atlas Network published an
extensive study profiling DNA methylation and RNA expression from hyper-mutated versus nonhypermutated categories of tumors (2012). They observed that non-hypermutated tumors,
regardless of CIMP status, displayed similar DNA methylation and gene expression patterns. In
accordance with previous studies, they found that hyper-mutated cancers were enriched for
hypermethylation and CIMP-H status, as well as BRAF mutations (Network 2012).
The mechanism underlying CIMP is not known. Several studies have reported that DNMT
overexpression underlies this phenotype (Nosho, Shima et al. 2009), but numerous reports have
refuted this mechanism (Eads, Danenberg et al. 1999). One study suggests that aberrant DNA
methylation in CRC may involve the repressive Polycomb complex. Widschwendter et al.
reported a 12-fold enrichment for Polycomb target sequences among hypermethylated regions in
CRC (2007). Polycomb repressive complexes interact with DNMTs in human cell lines, and the
EZH2 subunit of Polycomb is required to recruit DNMTs to H3K27-methylated CpGs (Viré,
Brenner et al. 2006). Thus, in cancer, EZH2 activity may attract DNA methylation to permanently
silence target genes, predisposing to cancer development.
Irizarry and colleagues performed genome-wide bisulfite sequencing in human colorectal
tumors to assess exactly where hypermethylation occurs relative to CGIs and transcription start
sites (2009). Interestingly, they found that hypermethylation in CRCs is enriched at CGI shores,
defined as the regions 2KB upstream and downstream of a respective CGI. The CGI enrichment
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data for CRCs are similar to the distribution they found for tissue-specific differentially methylated
regions (DMRs) in normal tissues (Irizarry, Ladd-Acosta et al. 2009). Furthermore, they found
nearly equal amount of hypo- and hyper-methylated CGI shores in CRC compared to normal
colon, suggesting that both types of methylation aberrations are involved in cancer formation.
Many of these so-called cancer DMRs were enriched for tissue-specific DMRs, such as spleen,
liver and brain, and gene ontology of the cancer-specific DMRs identified gene categories
involved in pluripotency and development (Irizarry, Ladd-Acosta et al. 2009). Thus, many of the
same pathways and tissues involved in development are altered in human CRC. This idea forms
the basis for the epigenetic progenitor model of cancer, in which aberrant activity of differentiation
pathways causes cancer (Jones and Baylin 2007).

DNA methylation in CRC: Lessons from Mouse models
The Apc

Min/+

model, based on human FAP, forms the basis for in vivo studies of intestinal

carcinogenesis. The Apc

Min/+

mice develop multiple tumors throughout the intestinal epithelium,

with microadenomas visible by 3 months of age (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992,
Laird, Jackson-Grusby et al. 1995). The earliest reports of the effects of DNA hypomethylation on
tumorigenesis in Apc

Min/+

mice utilized a combination of Dnmt1 hypomorphic alleles and the

pharmacological Dnmt inhibitor 5-aza-deoxycytidine (5-aza). Laird and colleagues produced
Apc

Min/+

;Dnmt1

S/+

hypomorphic mice, and treated them with 5-aza from one week of age to induce

DNA hypomethylation. At 100 days, they observed that the Apc
had only two intestinal polyps, compared to 113 in the Apc

Min/+

Min/+

;Dnmt1

S/+

5-aza treated mice

no 5-aza control. They concluded

that DNA hypomethylation is not a causative factor in intestinal tumor development, and that DNA
methylation is required for intestinal carcinogenesis.
Further studies enhanced this hypothesis, using varying Dnmt1 hypomorphic alleles on
the Apc

Min/+

background. Cormier and Dove (2000) used Apc

Min/+

;Dnmt1

N/+

mice to show that

Dnmt1 regulates both intestinal tumor incidence and size, and noted that tumor suppression in
this model was not dependent on p53. Eads and colleagues built on these data by constructing a
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Apc

Min/+

;Dnmt1

N/R

mouse line, which displayed severe hypomethylation and no polyp formation

(2002). They also found that these mice display reduced CGI hypermethylation at tumor
suppressor genes, and conclude that CGI hypermethylation is required for intestinal tumor
development (Eads, Nickel et al. 2002).
The most recent report more closely analyzes the varying stages of colonic tumor
development in the absence of Dnmt1 (Yamada, Jackson-Grusby et al. 2005). Apc

Min/+

;Dnmt1

chip/c

mice exhibit reduced DNA methylation and colon macroadenoma formation, as expected.
Interestingly, Apc

Min/+

;Dnmt1

chip/c

mice displayed increased numbers of colonic microadenomas,

suggesting that Dnmt1 is not required to initiate tumors, but is required for their sustained growth.
It should be noted that Apc
Apc

Min/+

Min/+

mice typically do not develop colonic tumors; unlike human FAP,

mice develop primarily intestinal tumors. Yamada et al.’s Apc
+

contain ~1 tumor per mouse, as opposed to the 100 tumors an Apc

Min/+

Min/+

colon controls only

intestine would produce

(Yamada, Jackson-Grusby et al. 2005). As a result, it is difficult to draw precise conclusions from
this model.
Due to the impact of the CIMP phenotype in human CRC research, the function of de
novo Dnmts in mouse tumor development has also been a significant area of research. Inducible
overexpression of Dnmt3a had no effect on colon tumorigenesis on the Apc

Min/+

background

(Linhart, Lin et al. 2007). In the same study, inducible overexpression of Dnmt3b increased the
number of colonic and intestinal macroscopic adenomas. Linhart and colleagues also report that
Dnmt3b overexpression increased de novo methylation at Sfrp2, Sfrp4, and Sfrp5, which are
endogenous suppressors of Wnt signaling (2007). Sfrp genes are common targets of promoter
hypermethylation in human CRCs (Suzuki, Watkins et al. 2004). In related studies in human
colorectal cancer cell lines, demethylation of Sfrp gene promoters reactivated the associated
genes, halting cell proliferation and inducing apoptosis (Suzuki, Watkins et al. 2004).
Additionally, Dnmt3b overexpression in Apc

Min/+

mice causes hypermethylation of similar

gene sets in both colonic tumors and adjacent normal epithelium. Dnmt3b had no effect on the
typical CIMP tumor suppressors, such as Mlh1 or Mgmt, implying that Dnmt3b targets specific
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genes for hypermethylation (Linhart, Lin et al. 2007). Overall, these results suggest that Dnmt3b
may promote the formation of colorectal cancers, and has a transformative effect on normal
colonic epithelium.
The same group also published a study assessing the requirement for Dnmt3b in Apc

Min/+

tumor development. They used the Cre-loxP recombination system to produce a colon-specific
Dnmt3b deletion on the Apc

Min/+

background. Lin and colleagues did not report any variation in

normal wild-type mucosa in the absence of Dnmt3b (2006). In Apc

Min/+

mice, loss of Dnmt3b led to

a significant decrease in the number of macroscopic colonic tumors, but did not affect
microadenoma initiation. The Dnmt3b deletion was fairly mosaic; only about half of
microadenomas demonstrated loss of Dnmt3b protein. All mature tumors, however, contained
+

patches of Dnmt3b cells, indicating an active selection against Dnmt3b-null microadenomas in
tumor development (Lin, Yamada et al. 2006). These results suggest that Dnmt3b is crucial for
progression to adenoma, but may not be essential to maintain a fully formed tumor.
Based on the above studies, one could conclude that DNA hypomethylation is
unimportant for tumor development. However, there are several problems with these studies that
remain to be addressed in the future. The above experimental models employed hypomorphic
Dnmt1 alleles, which caused hypomethylation in all tissues from early development onward. As a
result, the observed phenotypes may be due to developmental defects or intestine-independent
effects of hypomethylation. For instance, mesenchyme-specific transcription factors, such as
Foxl1, are important modifiers of the Apc

Min/+

phenotypes (Perreault, Sackett et al. 2005), and

may be affected in Dnmt1-hypmorphic mice. Dnmt1 is also required for embryonic development
(Li, Bestor et al. 1992), and may play an important role in organogenesis as well (Georgia, Kanji
et al. 2013). Although the role of Dnmt1 in the developing intestinal epithelium is unknown, in the
mature epithelium Dnmt1 supports differentiation processes and restricts the proliferative stem
cell zone (Sheaffer, Kim et al. 2014). Indeed, loss of Dnmt1 in the adult intestinal epithelium
causes a two-fold expansion of the crypt compartment (Sheaffer, Kim et al. 2014), suggesting
that methylation plays essential roles in regulating proliferative processes. Thus, it would be
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valuable to reassess the role of Dnmt1 in the Apc

Min/+

colorectal cancer model using epithelial

specific and/or inducible Cre-loxP mouse models. In this work, I describe the function of Dnmt1
during perinatal intestinal development and Apc

	
  

Min/+

	
  

intestinal cancer progression.
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Figure 1.1. The mammalian intestinal epithelium.
Longitudinal cross section of the adult intestinal epithelium. The intestinal epithelium is a single
cell layer lining the lumen of the intestine, and is structured into proliferative crypts and
differentiated villi. Crypts contain both proliferative CBC stem cells and quiescent +4 stem cells.
These stem cells give rise to rapidly dividing transit-amplifying cells, which begin differentiation as
they migrate out of the crypt. Secretory progenitors differentiated into goblet cells,
enteroendocrine cells, Paneth cells. Enterocyte progenitors develop into absorptive enterocytes,
which comprise ~90% of the epithelium.
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Figure 1.2. Opposing roles for epigenetic modifications in the intestinal epithelium.
(A,B) Cdx2 maintains the open chromatin state at enhancers during intestinal differentiation. In
proliferating cells Cdx2 is not bound at differentiation-enhancers, and these regulatory regions
display reduced H3K4me2 (A). As a result, these genes are not highly expressed. In
differentiating cells, Cdx2 and Hnf4a bind at enhancer regions marked by increased H3K4me2,
which activates expression of enterocyte-lineage genes (B). Cdx2 supports H3K4me2 dimethylation, presumably by MLL methyltransferase complex activity. Loss of Cdx2 binding in
these regions leads to reduced H3K4me2 in differentiated villus cells (Verzi, Shin et al.
2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al.
2013)(Verzi, Shin et al. 2013).
(C,D) DNA methylation at enhancers upstream of proliferation and/or stem cell genes regulates
cell division in crypts. In dividing intestinal cells, enhancers are unmethylated (C), allowing Cdx2
to bind and activate progenitor gene expression. In differentiated cells, enhancers associated with
stem cell genes are methylated (D). DNA methylation restricts access by transcription factors,
and genes are silenced.
(A,B) adapted from Verzi et al. 2010. (C,D) adapted from Sheaffer et al. 2014.
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Chapter 2
Materials and Methods

	
  

	
  

35	
  

General Protocols
Animals and genotype analysis Dnmt1

loxP/loxP

and Dnmt3b

loxP/loxP

mice were kindly provided by

Rudolf Jaenisch (Jackson-Grusby, Beard et al. 2001, Lin, Yamada et al. 2006), and
VillinCreERT2 mice were received from Sylvia Robine (el Marjou, Janssen et al. 2004). VillinCre
(Madison, Dunbar et al. 2002) and Apc

Min/+

mice (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992)

were obtained from The Jackson Laboratory. Genotyping was performed by PCR analysis. For
VillinCreERT2-mediated deletion experiments, Cre-recombination was induced by three daily
intraperitoneal injections of 1.6 mg tamoxifen (Sigma) in an ethanol/sunflower oil mixture.
Littermate controls without the VillinCreERT2 transgene also received tamoxifen treatment. For 2hour EdU analysis, I administered EdU by intraperitoneal injection 2 hours prior to dissection. I
administered 0.1 mg EdU (Invitrogen) for postnatal day 0 (P0) mice, and 1 mg EdU for 3-month
old adult mice. All procedures involving mice were conducted in accordance with approved
Institutional Animal Care and Use Committee protocols.
Histology, immunohistochemistry, and immunofluorescence Intestines were fixed O/N in 4%
paraformaldehyde and embedded in paraffin. Hematoxylin and eosin (H&E) staining were used to
assess global morphology of intestinal epithelial specimens. For all antibody staining, slides were
dewaxed and antigen retrieval was performed using the 2100 Antigen-Retriever and R-Buffer A
(Electron Microscopy Sciences). Standard immunohistochemistry staining was performed for
Dnmt1 (Santa Cruz 20701, 1:200), Ki67 (BD Pharmingen 550609, 1:500), and β-catenin (BD
Transduction 610153, 1:200) using the ABC detection system (Vector Laboratories). Briefly,
following antigen retrieval all slides were blocked with 3% H2O2, avidin, and biotin (Vector
Laboratories). Additionally, for staining of Dnmt1 slides were blocked for 30 minutes with CAS
Block (Invitrogen), and for staining of Ki67 and β-catenin slides were blocked for 15 minutes with
StartingBlock T20 blocking buffer (Thermo Scientific). Sections were incubated with respective
primary antibody at 4°C overnight, with the exception of Dnmt1, which was diluted in Antibody
Diluent Reagent Solution (Invitrogen). The next day, slides were incubated with biotinylated
secondary antibody (Vector Laboratories) followed by treatment with ABC reagent, and
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developed with DAB (Vector Laboratories). P21 immunohistochemistry (BD Pharmingen 556430,
1:50) was performed as described previously (van de Wetering, Sancho et al. 2002). Standard
immunofluorescence procedures were performed with the following antibodies: Chromogranin A
(Immunostar 20085, 1:200), Ki67 (BD Pharmingen 550609, 1:500), Dnmt3a (Santa Cruz 20703,
1:500), Dnmt3b (Imgenex 184A, 1:500), E-cadherin (BD Transduction Lab 610181, 1:500),
Epcam (Abcam 71916, 1:500), Lysozyme (Dako A0099, 1:3,000), Mucin2 (Santa Cruz 15334,
1:50), γH2AX (Cell Signaling 2577L, 1:250), and phosphorylated histone H3 (Cell Signaling 3377,
1:500). For E-cadherin, γH2AX, and PH3 staining, tissues were blocked for 15 minutes with CAS
Block (Invitrogen). For staining of Ki67, Chromogranin A, Lysozyme, Mucin2, Dnmt3a, and
Dnmt3b, tissues were blocked for 2 hours at room temperature with 5% normal donkey serum
(EMD Millipore) in 1% BSA in PBS. For Epcam and Ki67, sections were blocked for 15 minutes
with StartingBlock T20 blocking buffer (Thermo Scientific). All tissues were incubated with
respective primary antibody overnight at 4°C. The following day, slides were incubated with
immunofluorescent secondary antibodies (The Jackson Laboratory), counterstained with DAPI,
and mounted with fluorescence mounting medium. Co-staining was accomplished by sequential
immunohistochemistry and immunofluorescent antibody staining. Alkaline phosphatase staining
was performed using NBT and BCIP (Boehringer). Immunofluorescent TUNEL staining was
performed using TUNEL Label and Enzyme (Roche) and AlexaFluor 555-aha-dUTP (Life
Technologies). For cell replication analysis, we used the Click-iT EdU Alexa Fluor 555 Imaging Kit
(Invitrogen). All microscopy was performed on a Nikon Eclipse 80i.
mRNA expression analysis Small intestines and macroscopic tumors were isolated and
immediately frozen in Trizol (Invitrogen). RNA was extracted using the Trizol RNA isolation
protocol (Invitrogen), followed by RNA cleanup using the RNeasy Mini Kit (Qiagen). mRNA
expression was measured using quantitative RT-PCR, as described previously (Gupta, Gao et al.
2007). The SYBR green qPCR master mix (Agilent) was used in all qPCR reactions, and the fold
change was calculated relative to the geometric mean of Tbp and β-Actin, using the ΔCT method.
The method of normalizing to the geometric mean of a set of reference genes has been
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described previously (Vandesompele, De Preter et al. 2002). Primer sets can be found in Table
2.1.

Protocols specific for Chapter 3: Dnmt1 is essential to maintain progenitors in the
perinatal intestinal epithelium.
Cell counting in the Dnmt1-deficient neonatal intestine For villi quantification, H&E sections of
tissue were scanned at 10X using Metamorph imaging software (Molecular Devices). Per
biological replicate, villi were counted for ≥20 mm tissue, measured using ImageJ (Schneider,
Rasband et al. 2012). For TUNEL and γH2AX quantification, 500 intervillus cells were counted at
20X for each biological replicate. Intervillus cells were defined as 20 µm from the base of the
intestinal epithelium.
EdU quantification in the adult and neonatal intestinal epithelium For EdU quantification, I
harvested jejunum from five Dnmt1

loxP/loxP

3-month old adult mice, and three litters of Dnmt1

loxP/loxP

P0 mice (4 mice per litter). I defined the crypt-villus subunit as the epithelium lying between the
+

peaks of two adjacent villi that share the same crypt. I counted the total number of EdU nuclei
per crypt or intervillus region, and divided this number by the total number of nuclei per crypt
villus subunit. Per adult sample, I counted ~8 crypt-villus subunits. Per P0 sample, I counted ~25
crypt-intervillus subunits.
Laser capture microdissection, RNA-Seq, and mRNA expression analysis Laser capture
microdissection (LCM) was performed from unstained sections of paraffin-embedded, methacarnfixed proximal jejunum for 3 controls and 2 mutants, as described previously (Miyoshi, Ajima et al.
2012). For laser-capture microdissection (LCM), proximal jejunum was collected from
Dnmt1

loxP/loxP

; VillinCre neonatal litters. Tissue was fixed for one hour in cold methacarn solution

(60% methanol, 30% chloroform, 10% glacial acetic acid), washed 3 times in cold 70% ethanol,
and submitted for paraffin embedding and sectioning. Serial sections were cut for mutants
(Dnmt1

loxP/loxP

; VillinCre, n=2) and controls (Dnmt1

loxP/+

, n=3). Odd numbered sections were

mounted onto charged glass slides, and were used for Ki67 IF staining as described above. Ki67
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stained sections were scanned using a 10X objective and Metamorph imaging software; scans
served as the map for LCM on unstained sections. Even numbered sections were mounted onto
non-charged glass slides for use in LCM.
The PixCell II LCM system (Arcturus, Applied Biosystems; 7.5-µm diameter laser spot)
-

+

was used to capture Ki67 intervillus cells from mutants (n=2) and Ki67 intervillus cells from
controls (n=3). Captured cells were collected onto CapSure HS LCM caps (Applied Biosystems),
and total cellular RNA was extracted using the PicoPure RNA isolation kit (Applied Biosystems).
RNA concentration and quality was assessed on an Agilent 2100 Bioanalyzer (Agilent
Technologies). Total RNA isolated by LCM (2.3 ng to 33.3 ng per sample) was amplified using
the Ovation RNA-Seq System V2 (NuGEN). 300 ng of each sonicated cDNA sample was used for
RNA-Seq library preparation. cDNA sequencing libraries were completed using NEBNext Ultra
RNA Library Prep Kit for Illumina (New England Biolabs), Illumina multiplexing adaptors, and the
NEBNext ChIP-Seq DNA Sample Prep Reagent Set 1 Kit (New England Biolabs). Single-read
sequencing was performed on the Illumina HiSeq 2000 (100 bp reads).
Reads (a minimum of 25 million per sample, ~80% unique mapped reads) were aligned
to the mouse reference genome (NCBI build 37, mm9) using TopHat (Trapnell, Roberts et al.
2012). TopHat was run with the University of California at Santa Cruz refFlat annotation file (GTF
format) and the “–no-novel-juncs” option to map reads only in the reference annotation. Cutdiff
was used to calculate gene expression levels (Trapnell, Roberts et al. 2012). Messenger RNA
levels were expressed in reads per kilobase of transcript per million mapped reads (RPKM).
Gene Ontology analysis was performed using DAVID (Ashburner, Ball et al. 2000). Cutdiff results
were filtered by FDR<0.1, and separated into two categories, upregulated genes and
downregulated genes. DAVID functional annotation analysis was performed separately for each
gene set.
RNA isolation and qRT-PCR to confirm RNA-Seq For confirmation of RNA-Seq results,
proximal jejunal RNA samples were collected by Laser Capture Microdissection using a Leica
LMD7000 Laser Microdissection microscope, as described above. Approximately 10,000 cells
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were collected per sample. RNA was isolated and cDNA amplified using the protocols described
for the RNA-Seq libraries. The SYBR green qPCR master mix (Agilent) was used in all qPCR
reactions, and the fold change was calculated relative to the geometric mean of five reference
genes: Tbp, b-Actin, Rplp0, Polr2b, and B2m using the ΔCT method. Primer sets can be found in
Table 2.1.
Organoid culture For neonatal Dnmt1

loxP/loxP

(n=3) and Dnmt1

loxP/loxP

; VillinCre (n=2) organoid

culture, duodenum and jejunum were opened longitudinally in cold PBS, cut into 10mm pieces,
and incubated in EDTA. Vigorous pipetting released the epithelia from the tissue, and cells were
embedded in Matrigel (BD Biosciences) for cell culture, as described previously (Sato, Vries et al.
2009). All organoids were grown at 37°C, 5% CO2. Cell media (Advanced DMEM/F12, Invitrogen)
was supplemented with GlutaMax (Invitrogen), Hepes (Invitrogen), Pen/Strep (Invitrogen), N2
(Invitrogen), B27 (Invitrogen), and N-Acetylcysteine (Sigma). The following growth factors were
added to media: mEGF (Invitrogen), mNoggin (Peprotech), hR-Spondin (Peprotech). For the first
two days of neonatal organoid growth, cultures were also supplemented with Y-27632 (Sigma)
and CHIR-99021 (Biovision). The medium was changed every other day.
Crypts were isolated from jejunum of 3-month-old Dnmt1
Dnmt1

loxP/loxP

loxP/loxP

; VillinCreERT2 (n=4) and

(n=2) mice for organoid culture as described previously (Sato, Vries et al. 2009).

The following growth factors were added to media: mEGF (Invitrogen), mNoggin (Peprotech), hRSpondin (Peprotech), and CHIR-99021 (Biovision). The medium was changed every other day.
For VillinCreERT2 induction, 4-hydroxytamoxifen (Sigma H7904) was added to organoid media at
a final concentration of 100nm (Sato, Vries et al. 2009). After 48 hours, the 4OHT medium was
removed and fresh medium was added to each well. The 100nm concentration was not
detrimental to Dnmt1

loxP/loxP

control organoids at either time point (Fig. S10 and S11).

2 hours prior to organoid harvest, EdU (Invitrogen) was added to each well (10mm).
Organoids were harvested using cold PBS, and were fixed in 4% PFA for 1 hour at 4°C. Organoid
pellets

were

suspended

in

agarose,

embedded

in

paraffin,

and

sectioned

for

immunohistochemistry analysis.
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Laser capture microdissection and targeted bisulfite sequencing DNA was isolated from
paraffin-embedded tissue sections using a Leica LMD7000 Laser Microdissection microscope
and the Arcturus PicoPure DNA isolation kit (Applied Biosystems). LCM-isolated DNA was
bisulfite-converted and purified using the Epitect Bisulfite Kit (Qiagen). Template DNA was
amplified using the KAPA HiFi HotStart Uracil+ ReadyMix PCR Kit (Kapa Biosystems). The
LINE1 and H19 PCR assays were described previously (Lane, Dean et al. 2003, Samuel, Suzuki
et al. 2009). Additional primer sets were designed using PyroMark software (Qiagen) and are
listed in Table 2.2. Adult Dnmt1

loxP/loxP

;VillinCreERT2 mutant and Dnmt1

loxP/loxP

control crypt DNA

were kindly provided by K.L.Sheaffer (Sheaffer, Kim et al. 2014).
Sequencing libraries were made using the Ovation SP Ultralow Library system and
Mondrian SP+ Workstation (NuGEN). Libraries were pooled at 8 nM, and 150bp paired end
sequencing was performed on the Illumina MiSeq (MiSeq v2 Reagent Kit, 300 cycles PE).
Converted sequence was aligned to the mouse genome (NCBI build 37, mm9) using BS Seeker
(Chen, Cokus et al. 2010).
Data Access All RNA sequencing data generated in this study have been deposited in the NCBI
Gene Expression Omnibus (Edgar, Domrachev et al. 2002) under accession number GSE67363.
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Protocols specific for Chapter 4: Dnmt1 and Dnmt3b are required for genomic stability in
intestinal epithelial homeostasis.
Tumor evaluation procedures Macroscopic tumors were counted immediately after tissue
isolation using a stereoscope. Microadenoma counts were performed on sections stained with
hematoxilyn and eosin (H&E) for the small intestine and sections stained with β-catenin for the
colon. Microadenoma size was calculated by measuring the width of neoplastic lesions on H&E
stained small intestine sections using ImageJ (Schneider, Rasband et al. 2012). Histological
pathology was performed as described previously (Boivin, Washington et al. 2003).
Loss of heterozygosity at the Apc locus Tumor and non-tumor epithelial cell DNA were
collected using a Leica LMD7000 Laser Microdissection microscope and the Arcturus PicoPure
DNA isolation kit (Applied Biosystems). LOH was performed as done previously (Luongo, Moser
et al. 1994).
Phosphorylated-H3 cell cycle quantification Apc
sibling Apc

Min/+

;Dnmt1

loxP/loxP

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutants and

controls were injected with tamoxifen at 1 month of age. Small

intestines were collected one month and two months following tamoxifen administration, in
separate cohorts of mice. Following fixation, tissue sections were co-stained for phosphorylated
histone H3 (PH3) to identify cells in M-phase, and β-catenin to identify hyper-proliferative
+

neoplastic epithelium. I counted the number of PH3 nuclei, and divided it by the total number of
nuclei in the respective region. This calculation was performed for neoplastic intestinal epithelium
at both time points, for controls and mutants.
Laser capture microdissection Tumor and non-tumor epithelial cell DNA was collected using a
Leica LMD7000 Laser Microdissection microscope and the Arcturus PicoPure DNA isolation kit
(Applied Biosystems).
Targeted bisulfite sequencing 100 ng of mouse genomic DNA was bisulfite converted using the
Epitect bisulfite kit (Qiagen). Template DNA was amplified using the KAPA HiFi HotStart Uracil+
ReadyMix PCR Kit (Kapa Biosystems) with primers directed to the H19 ICR and LINE1 region
and modified with partial Illumina adapter overhangs (PCR#1 F/R). Samples were barcoded by
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incorporation of a unique DNA sequencing barcode in a subsequent round of PCR amplification
(PCR#2 F/R). Samples were pooled at 2nM, and 150bp paired end sequencing was performed
on the Illumina MiSeq (MiSeq v2 Reagent Kit, 300 cycles PE). Converted sequences were
aligned to the mouse genome (NCBI build 37, mm9) using BS Seeker (Chen, Cokus et al. 2010).
Primer sequences can be found in Table 2.3.
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Chapter 3
Dnmt1 is essential to maintain progenitors in the perinatal
intestinal epithelium
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Abstract
The DNA methyltransferase Dnmt1 maintains DNA methylation patterns and genomic
stability in several in vitro cell systems. Ablation of Dnmt1 in mouse embryos causes death at the
post-gastrulation stage; however, the functions of Dnmt1 and DNA methylation in organogenesis
remain unclear. Here, I report that Dnmt1 is crucial during perinatal intestinal development. Loss
of Dnmt1 in intervillus progenitor cells causes global hypomethylation, DNA damage, premature
differentiation, and apoptosis, and consequently, loss of nascent villi. I further confirm the crucial
role for Dnmt1 during crypt development using the in vitro organoid culture system, and illustrate
a clear differential requirement for Dnmt1 in immature versus mature organoids. These results
demonstrate an essential role for Dnmt1 in maintaining genomic stability during intestinal
development and the establishment of intestinal crypts.
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Introduction
DNA methyltransferase 1 (Dnmt1) maintains DNA methylation following DNA replication,
but little is known about its requirement for organ development. Previous studies of mice with
global deletion of Dnmt1 failed to define the contribution of maintenance methylation during
organogenesis, because Dnmt1 null mice die shortly after gastrulation, at approximately
embryonic day 9.5 (E9.5) (Li, Bestor et al. 1992). With the advent of Cre-loxP recombination
technology and tissue specific gene ablation, the role of Dnmt1 in organ development can now be
addressed. For example, Dnmt1 has been ablated during neuronal development and shown to be
essential for the survival of fetal mitotic neuroblasts (Fan, Beard et al. 2001). Dnmt1-ablated
neuroblasts are 95% hypomethylated, and mice die just after birth due to respiratory defects,
demonstrating a clear role for Dnmt1 in organ development and cellular differentiation (Fan,
Beard et al. 2001). In the fetal pancreas, deletion of Dnmt1 causes a decrease in differentiated
pancreatic cells with a concomitant increase in p53 levels, cell cycle arrest, and progenitor cell
apoptosis. However, this phenotype is dependent on direct binding of the Dnmt1 protein to the
p53 (Trp53) locus, and was suggested to be caused by a DNA-methylation independent effect of
Dnmt1 (Georgia, Kanji et al. 2013). Thus, it remains unclear whether and how Dnmt1 and
maintenance DNA methylation control different organs during development.
The intestinal epithelium is an especially tractable system for the study of stem cell
maintenance and cellular differentiation. Important differences between the neonatal and adult
intestinal epithelium led us to investigate the role for Dnmt1 during fetal gut development.
Previous work had shown that Dnmt1 controls cellular differentiation in the mature intestinal
epithelium, but is dispensable for organ maintenance and organismal survival in adult mice
(Sheaffer, Kim et al. 2014). However, the intestinal stem cell niche does not develop until
approximately one week after birth in mice. During fetal gut development, proliferative progenitor
cells become progressively restricted to the intervillus epithelium. Following birth, the proliferative
intervillus regions invaginate into the underlying mesenchyme to form intestinal crypts. As a
result, there is no defined stem cell population in the late fetal and perinatal intestinal epithelium.
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Furthermore, the mitotic index of intestinal epithelial progenitors is highest during the late
embryonic and postnatal period, during which time the rate of cell production must dramatically
exceed the rate of cell extrusion at the villus tip to allow for rapid villus growth (Al-Nafussi and
Wright 1982, Itzkovitz, Blat et al. 2012). This higher rate of cell turnover may indicate a distinct
requirement for maintenance DNA methylation, as any delay in cell division would be expected to
impair organ development.
Prior studies have failed to provide a clear explanation as to why loss of DNA methylation
during organ development, such as in the brain, causes cell death (Fan, Beard et al. 2001).
Rescue of the cell death phenotype in Dnmt1-deficient cultured fibroblasts via inactivation of
Trp53 strongly suggests that the p53 pathway is partially responsible (Jackson-Grusby, Beard et
al. 2001). In vitro studies of colorectal cancer (CRC) cell lines demonstrate that loss of DNA
methylation results in genomic instability, DNA damage, and mitotic arrest (Chen, Hevi et al.
2007). Indeed, hypomethylation leads to increased mutation rates and reduced genomic stability
(Chen, Pettersson et al. 1998), and in human CRC patients aberrant DNA methylation correlates
with microsatellite instability (Ahuja, Mohan et al. 1997). Therefore, I set out to determine if loss of
Dnmt1 causes genomic instability and intestinal development failure in the developing gut.
Using cell type-specific gene ablation, I discover that Dnmt1 is essential for the
maintenance of epithelial proliferation and nascent crypt development in the perinatal period.
Without maintenance DNA methylation, the rapidly growing epithelium displays increased doublestrand breaks, activation of the DNA damage response, and loss of progenitor cells due to both
premature differentiation and apoptosis. I validate these results utilizing in vitro organoid cultures,
demonstrating that Dnmt1 is required to establish organoids from the perinatal intestinal
epithelium, but is not essential for the maintenance of mature organoids derived from adult
intestinal crypts. These data provide novel evidence for the role of DNA methylation in
maintaining genomic stability during the development of highly proliferative tissues.
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Results

Dnmt1 is expressed in the proliferative zone of the embryonic and adult intestinal
epithelium
To begin my study of the requirement for Dnmt1 in intestinal epithelial development, I first
characterized the localization of Dnmt1 protein at different fetal and postnatal stages in the
mouse. At E16.5, E18.5, and on postnatal day 0 (P0), Dnmt1 protein was restricted to the
proliferative intervillus regions, while in the adult intestinal epithelium, Dnmt1 was localized to the
proliferative crypt zone, as previously reported (Figure 3.1) (Sheaffer, Kim et al. 2014).
Furthermore, prior RNA-Seq analysis of isolated cell populations from the adult intestinal
+

epithelium confirms that Lgr5 crypt-based columnar intestinal stem cells (ISCs) express Dnmt1,
while differentiated villus cells contain little to no Dnmt1 mRNA (Sheaffer, Kim et al. 2014).

Dnmt1 ablation causes decreased proliferation and genome hypomethylation in the
perinatal intestinal epithelium
To investigate the function of Dnmt1 during murine gut development, I employed CreloxP recombination technology to specifically ablate Dnmt1 in the intestinal epithelium. The
VillinCre transgene has been shown to cause activation of a Cre-dependent lacZ reporter as early
as E12.5 (Madison, Dunbar et al. 2002), but analysis of late gestation Dnmt1

loxP/loxP

;VillinCre

E18.5 embryos revealed highly mosaic ablation of Dnmt1 (Figure 3.2 A-C), and no phenotypic
effects were observed at this stage (data not shown). The mosaicism can be explained by the fact
that the efficacy of Cre-mediated gene ablation varies depending on the design of the loxPflanked target allele and its localization in chromatin (Baubonis and Sauer 1993, Long and Rossi
2009). Because Dnmt1

loxP/loxP

;VillinCre mutants were born at the expected Mendelian ratios, I set

out to determine the potential requirement for Dnmt1 in the perinatal period.
The majority of Dnmt1

loxP/loxP

;VillinCre mutant mice died within the first weeks of life, with

only ~35% surviving to weaning (Figure 3.3 A). The variable expressivity of the mutant phenotype
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is explained by the mosaicism of gene ablation in Dnmt1

loxP/loxP

;VillinCre mice. In the first week of

life, mutant mice often became runted and failed to compete with healthy littermates for maternal
resources. I thus confined my analyses to postnatal day 0 (P0) Dnmt1

loxP/loxP

;VillinCre mice.

Staining of mutant P0 intestine revealed that Dnmt1 protein was absent from 40-60% of
progenitor cells (Figures 3.3 C,E and 3.4 A-C). Quantification of the villi present in the mutant
neonatal intestinal epithelium showed a 25% decrease in villus number compared to littermate
controls (Fig. 3.3 B); the length of the villi, largely reflecting areas in which Dnmt1 had not been
deleted, remained similar across genotypes (data not shown).
To evaluate the possibility that the de novo DNA methyltransferases Dnmt3a and Dnmt3b
might compensate for Dnmt1 deficiency during gut development, I determined mRNA expression
and protein localization of these two enzymes in Dnmt1
Dnmt1

loxP/loxP

loxP/loxP

;VillinCre neonatal mutants and

littermate controls. The Dnmt1-deficient intestine did not display increased mRNA

expression or altered localization of either de novo methyltransferase (Figure 3.4 D-I). Thus, there
is no compensatory upregulation of expression of Dnmt3a and 3b in the Dnmt1-deficient gut
epithelium.
The intestinal epithelium of surviving adult Dnmt1

loxP/loxP

;VillinCre mutants was

+

predominantly Dnmt1 , indicating that “escaper cells” that avoided Cre-mediated excision had
repopulated the intestinal epithelium in its entirety (Figure 3.2 D-E). The fact that the epithelium of
surviving Dnmt1

loxP/loxP

;VillinCre mice is made up primarily of Cre-escaper cells, despite the fact

that the Villin promoter is active throughout adulthood, demonstrates that Dnmt1-deficient
+

progenitor cells are at a severe disadvantage compared to Dnmt1 , Cre-escaper cells.
To investigate the possible causes for the observed postnatal lethality in Dnmt1-deficient
mice, I first assessed epithelial cell proliferation. In control Dnmt1

loxP/loxP

littermates, all Dnmt1

+

+

cells are Ki67 ; I defined these proliferative areas in the intervillus regions of the neonatal
intestine as the progenitor zone (Figures 3.3 C-D and 3.5 A-B). The Dnmt1-ablated epithelium
displayed a striking reduction in the number of replicating cells as indicated by Ki67 staining, with
many intervillus regions lacking proliferative cells completely (Figures 3.3 E-F and 3.5 C-D).
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Regions of the gut that retained Dnmt1 expression due to inefficient Cre-mediated gene ablation
maintained epithelial proliferation, as expected (Figure 3.3 E-F). Furthermore, co-staining of
Dnmt1

loxP/loxP

;VillinCre mutants and littermate controls demonstrated the substantial overlap of

Dnmt1 and Ki67 protein localization (Figure 3.5). These results suggest that Dnmt1 is necessary
to maintain the proliferation of epithelial progenitors during early postnatal intestinal development.
Next, I determined if ablation of Dnmt1 resulted in loss of global DNA methylation in
progenitor cells. The mosaicism of the Dnmt1 mutants precluded mechanistic analysis in bulk
tissue extracts. To overcome this limitation, I isolated Dnmt1
Dnmt1

loxP/+

loxP/loxP

;VillinCre mutant and

control jejunal progenitor cells by laser-capture microdissection (LCM). I stained serial

sections for Ki67 to identify Dnmt1-ablated and Dnmt1-positive areas corresponding to nonproliferative and proliferative progenitor zones, respectively, and used the adjacent serial sections
for LCM. I isolated approximately 10,000 cells per biological replicate for DNA methylation
analysis (n=4 per group). LINE1 repetitive elements comprise 18% of the mouse genome
(Waterston, Lindblad-Toh et al. 2002) and are a representative measure of genome-wide DNA
methylation (Lane, Dean et al. 2003, Yang, Estécio et al. 2004). Bisulfite-sequencing of LINE1
elements demonstrated global demethylation of the mutant genome, exceeding 50% for several
CpGs, confirming a dramatic loss of maintenance methylation (Figure 3.3 G). To further probe the
DNA methylation status of mutant cells, I also bisulfite-sequenced the imprinting control region
(ICR) of the H19 locus. The H19 ICR is methylated on the paternal allele, meaning that H19 is
only expressed from the maternally inherited copy (Tremblay, Saam et al. 1995). Targeted
bisulfite-sequencing demonstrated a consistent reduction of DNA methylation at the H19-ICR
locus in mutants compared to controls (Figure 3.3 H). These data likely still underestimate the
degree of methylation loss, as even the most careful LCM resulted in the capture of 10% Dnmt1

+

cells from mutant tissues, as indicated by my RNA-Seq analysis (see below, Figure 3.6 B).
Overall, these bisulfite-sequencing results indicate a genome-wide reduction in DNA methylation.
To determine the changes Dnmt1 ablation causes in gene expression, I isolated
Dnmt1

	
  

loxP/loxP

;VillinCre mutant and Dnmt1

loxP/+

control progenitor cells using infrared (IR) laser
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capture on the Arcturus PixCell IIe (Figure 3.7 A-B). I isolated approximately 10,000 cells from the
proximal jejunum of each biological replicate and performed RNA-Seq to investigate the global
transcriptome of intervillus progenitor cells. By combining the transcriptome data with my
immunostaining analysis, I was able to correlate gene expression changes with protein
expression and localization alterations in the Dnmt1-ablated intestinal epithelium.
I found that Dnmt1 expression was reduced by ~90% in our mutant samples, with the
remaining Dnmt1 transcripts stemming from contaminating mesenchymal or Cre-escaper cells, as
indicated by RNA-Seq analysis of Dnmt1 exon 5, which is excised upon Cre-activation (JacksonGrusby, Beard et al. 2001) (Figure 3.6 B). By contrast, Dnmt3a and Dnmt3b mRNA levels were
unaffected, in agreement with my previous observations (Figure 3.6 A). Several imprinted genes,
including H19, were misregulated in mutant cells (Table 3.1), as expected. DAVID gene ontology
(GO) analysis (Ashburner, Ball et al. 2000) did not define any specific terms for upregulated
genes in Dnmt1-mutants, although I found increased expression of several differentiation-related
genes (Table 3.1 and Figure 3.7 C).

Partial induction of differentiation markers in Dnmt1-deficient progenitor zones
To test the possibility of premature differentiation of progenitor cells, I combined my RNASeq results with immunostaining for markers of differentiated cells present in the neonatal
intestine, including enterocytes, Goblet cells, and enteroendocrine cells. These experiments did
not reveal consistent differences in Goblet cell differentiation and localization compared to agematched controls (Figure 3.8 M-P). There were small but statistically significant increases in
alkaline phosphatase (Alpi) and chromogranin A (Chga) expression in mutant progenitors as
determined by RNA-Seq (Table 3.1). However, the vast majority of mutant intervillus progenitor
+

+

cells were neither Alpi nor Chga (Figure 3.8 A-H), suggesting that premature differentiation is
not the predominant cause of the Dnmt1-mutant phenotype.
+

Lysozyme Paneth cells do not appear in the normal mouse intestinal epithelium until
crypt maturation begins at ~P10, and drastically increase in number from P14 to P24 during crypt
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fission (Bry, Falk et al. 1994). Interestingly, lysozyme (Lyz) expression was markedly increased in
Dnmt1-ablated intestinal progenitors relative to controls by RNA-Seq, immunofluorescent
staining, and qRT-PCR (Table 3.1, Figures 3.7 D-E, 3.8 I-L, and 3.6 C, respectively). Further
analysis of RNA-Seq data showed that mutant progenitors exhibit increased expression of
several Paneth-cell related genes, including Ang4, Defa20, and Pla2g2a (Table 3.1) (Bevins and
Salzman 2011). Thus, it appears that a fraction of mutant progenitors halt the cell cycle and
prematurely differentiate into Paneth cells. However, my staining clearly indicates that only a
small fraction of mutant progenitors are differentiated (Figures 3.7 D-E and 3.8 I-L), suggesting
that other pathways, such as apoptosis, may also be activated. It is important to note that the
perinatal progenitor zone is not a homogeneous stem cell population; indeed, there may be
subpopulations of different progenitor cell types that are leading to the variable phenotypes we
observe.

Dnmt1-ablated progenitor cells exhibit altered mRNA expression and DNA methylation of
cell cycle and DNA damage response genes
GO analysis of downregulated genes indicated significant enrichment for the GO terms
‘cell division’, ‘DNA replication’, and ‘DNA damage response’ (Figure 3.7 C). A subset of these
misexpressed genes, including Atm, Chek2, p21 (p21

CIP1/WAF1

or Cdkn1a), and Mlh1 were

confirmed in three independent LCM samples by qRT-PCR (Figure 3.6 C-D). These results
demonstrate that loss of Dnmt1 caused decreased expression of DNA damage response and
cell- cycle related genes. Dnmt1 is known to play a crucial role in genomic stability, as ablation of
Dnmt1 in cell lines can result in mitotic defects and G2/M arrest (Chen, Hevi et al. 2007), or DNA
replication errors and activation of the G1/S checkpoint (Knox, Araujo et al. 2000, Unterberger,
Andrews et al. 2006). Additionally, loss of Dnmt1 in murine embryonic stem cells increases
mitotic mutation rates (Chen, Pettersson et al. 1998), further pointing to the necessity of Dnmt1 in
maintaining genomic integrity.
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My RNA-Seq data showed increased expression of the p53 target p21, which has an
established role in activating the G1/S and G2/M phase checkpoints and inducing cellular
senescence (Table 3.1 and Figure 3.6 D) (Deng, Zhang et al. 1995, Bunz, Dutriaux et al. 1998).
p21 is often increased in response to DNA damage, and inhibits the transcription of many genes
involved in cell cycle progression, leading to cell cycle arrest (Chang, Watanabe et al. 2000).
Furthermore, p21 has been shown to be upregulated in response to loss of Dnmt1 in CRC cell
lines (Chen, Hevi et al. 2007), and several studies suggest that p21 expression is controlled by
DNA methylation (Allan, Duhig et al. 2000, Zhu, Srinivasan et al. 2003, Brenner, Deplus et al.
2005). Immunostaining confirmed an increase in p21 protein levels in the Dnmt1-ablated
intervillus epithelium compared to control progenitor cells, while p21 levels in postmitotic villus
cells were comparable between the two genotypes (Figure 3.7 F-I). Taken together, my
transcriptome and immunostaining analyses suggest that Dnmt1-deficient cells undergo cell cycle
arrest.
To further interrogate the extent of hypomethylation and the mechanism underlying the
Dnmt1

loxP/loxP

;VillinCre mutant phenotype, I performed laser capture microdissection (LCM) and

targeted bisulfite sequencing near the promoter regions of Atm, Chek2, p21, and Mlh1. I
examined the methylation near the transcription start site (TSS) of these genes, but due to the
presence of CpG islands in the proximal promoters of all four genes, the baseline methylation
levels in controls were only 0-5% (data not shown). Next, I analyzed low-density CpGs clusters in
putative regulatory regions 2 to 4 kb upstream of the respective transcription start site, and found
that in all four cases the regions analyzed were significantly demethylated in the Dnmt1-deficient
gut epithelium compared to control (Figure 3.9). The drastic loss of DNA methylation correlated
with either increased or decreased mRNA levels, depending on the specific gene (Table 3.1 and
Figure 3.6 C-D), suggesting that the upstream regulatory elements analyzed might function as
enhancer (p21) or silencer (Chek2, Atm, Mlh1) regions (Jones and Takai 2001).

	
  

	
  

56	
  

Dnmt1 ablation results in increased DNA damage and apoptosis in the progenitor zone
Given the activation of apoptosis reported in other models following loss of Dnmt1 (Li,
Bestor et al. 1992, Jackson-Grusby, Beard et al. 2001, Chen, Hevi et al. 2007), I investigated the
levels of apoptosis and DNA damage in mutant intestinal progenitors. In control progenitor
regions, as expected, there were no apoptotic cells, as dying epithelial cells are normally confined
to the villus tip (Figure 3.10 A) (Hall, Coates et al. 1994). Surprisingly, I found a significant
number of apoptotic progenitor cells in mutant tissue (Figure 3.10 B), increased more than fiftyfold relative to littermate controls (Figure 3.10 C). To evaluate if increased apoptosis was
confined to Dnmt1-deficient, non-replicating intervillus cells, I co-stained to confirm loss of Ki67 in
TUNEL-positive areas (Figure 3.11 A-F). These data demonstrate that ablation of Dnmt1 not only
blocks proliferation, but also induces cell death in the progenitor compartment of the perinatal
intestine. The variability in the amount of cells undergoing apoptosis at any one point in time
reflects the stochastic cell death observed in the global Dnmt1-mutant embyros (Li, Bestor et al.
1992, Jackson-Grusby, Beard et al. 2001), but may also be due to the action of Cre in progenitor
cells at different points during development.
I considered the possibility that apoptosis of Dnmt1-deficient progenitors might be the
result of activation of the DNA damage response. Hypomethylation causes genomic instability
and increased mutation rates, which can lead to activation of cell cycle checkpoints and the DNA
damage response (Chen, Pettersson et al. 1998, Chen, Hevi et al. 2007, Loughery, Dunne et al.
2011). In addition, my own data demonstrate increased p21 levels in Dnmt1-mutant intervillus
cells (Figure 3.7 G-H), which indicates cell cycle arrest. To assess DNA damage response
activation in our mutants directly, I stained for γH2AX foci, which accumulate at double-stranded
DNA breaks (Figures 3.10 D-E and 3.11 G-L). I found a more than 1,000-fold increase in γH2AX
foci (p<0.001) in the mutant intervillus intestinal epithelium relative to littermate controls (Figure
3.10 F, compare red brackets in 3.10 D&E).

These results indicate loss of Dnmt1 causes

increased DNA damage, cell cycle arrest, and subsequent cell death.
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Adult Dnmt1-ablated crypt cells maintain methylation of DNA damage response genes
Given the opposing phenotypes we describe above for the neonatal intestine versus that
observed in mice with Dnmt1 ablation in the adult gut epithelium (Sheaffer, Kim et al. 2014), I also
analyzed DNA methylation in the adult crypt epithelium. Global methylation of repetitive LINE1
elements and the imprinted H19 locus is reduced in adult mice with intestinal epithelial-specific
Dnmt1 ablation to about the same extent as that seen in the perinatal ablation model described
here (compare Figure 3.12 A-B to 3.3 G-H). Strikingly, however, p21 and Chek2 are not
demethylated in the adult Dnmt1 ablation model (Figure 3.12 C-D), and Atm is only significantly
demethylated when comparing the entire sequenced region relative to control crypt epithelium
(Figure 3.12 E). Mlh1 is demethylated to a greater extent than the other genes analyzed (Figure
3.12 F), indicating that Mlh1 is particularly sensitive to loss of Dnmt1. These results demonstrate
that loss of Dnmt1 in the adult epithelium is not equivalent to the loss of Dnmt1 in the neonatal
epithelium. I postulate that the differing requirement for Dnmt1 maintenance DNA methylation
between the adult crypt compartment and the intervillus regions of the neonatal gut might be
related to the more than 2-fold higher fractional proliferation rate of the latter compared to the
former (Figure 3.13; (Itzkovitz, Blat et al. 2012)). I next sought to determine the differential
requirement for Dnmt1 in developing versus mature intestinal epithelial crypts in an in vitro
organoid culture system.

Dnmt1 is required for establishing organoids in vitro
To demonstrate that Dnmt1 is required for organoid crypt culture from perinatal intestine,
I employed EDTA-disassociation to isolate intestinal epithelia from postnatal day 1 (P1)
Dnmt1

loxP/loxP

;VillinCre mutants and Dnmt1

loxP/loxP

littermate controls (Figure 3.10 G). I grew these

perinatal organoid cultures in Matrigel with the ‘ENR’ (EGF, Noggin, R-Spondin) growth factor
cocktail, allowing me to observe the development and maintenance of the perinatal intestinal
epithelium in real time (Sato, Vries et al. 2009). I counted the number of organoids per well on
days 3-5 of culture, and observed very few organoids (<10 per well) established from the
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Dnmt1

loxP/loxP

;VillinCre mutant intestinal epithelium compared to the robust establishment of

organoids (>150 per well) from control gut (Figure 3.10 H). On day 4, I observed nascent buds in
the control Dnmt1
Dnmt1

loxP/loxP

loxP/loxP

organoids (Figure 3.10 K), but little sustained growth from the

;VillinCre mutant organoids (Figure 3.10 L). By day 5, it was apparent that no

healthy, budding organoids were produced from the Dnmt1-mutant intestine relative to littermate
controls (Figure 3.10 H,M,N). These results strongly support my in vivo data showing that Dnmt1
is essential to maintain perinatal intestinal progenitor cells.
To further probe the mechanism underlying the difference between the neonatal and
adult Dnmt1-ablation phenotypes, I employed Dnmt1

loxP/loxP

;VillinCreERT2 (Sheaffer, Kim et al.

2014) mice for in vitro organoid experiments. The VillinCreERT2 transgene allows temporal
control of Dnmt1 ablation via addition of 4-hydroxytamoxifen (4OHT) to cells in culture. I
hypothesized that Dnmt1 might be necessary for establishing the crypt compartment in neonatal
mice, but not be required for the maintenance and survival of mature crypts in adult mice. To test
this hypothesis, I isolated crypts from adult Dnmt1

loxP/loxP

and Dnmt1

loxP/loxP

;VillinCreERT2 mice,

and ablated Dnmt1 at two different time points during organoid growth. In one set of experiments,
I added 4OHT during the first two days of culture, when organoids are growing but have not yet
established buds and crypt structures (Sato, Vries et al. 2009) (Figure 3.14 A). For the second set
of experiments, I added 4OHT on days 5-7 of culture, after organoids had established proper
crypt hierarchy in budding outgrowths (Sato, Vries et al. 2009) (Figure 3.15 A).
In the “early” experiments, in which Dnmt1 had been acutely ablated by addition of
4OHT, Dnmt1-deficient organoids failed to grow beyond small cyst-like structures, while control
organoids began to exhibit buds by day 4 (Figure 3.14 B-E). Dnmt1 immunostaining confirmed
+

loss of the enzyme in 4OHT-treated VillinCreERT2 organoids (Figure 3.14 I). Addition of EdU to
media 2 hours prior to cell harvest allowed analysis of replication rate. There were almost no
+

EdU cells in the 4OHT-treated, Dnmt1-ablated organoids, in contrast to controls in which
replicating cells were abundant (Figure 3.14 J-M). TUNEL staining demonstrated an increase in
+

the frequency of TUNEL apoptotic nuclei in surviving Dnmt1-ablated organoids compared to
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controls (Figure 3.14 N-Q). Overall, the loss of Dnmt1 during the establishment of organoid
cultures parallels the phenotype seen in the perinatal Dnmt1

loxp/lxop

; VillinCre mutant intestine,

strongly suggesting a unique role for Dnmt1 in crypt development.
In stark contrast, the addition of 4OHT on days 5-7 of organoid culture, after large, multicrypt organoids had formed, had little effect on the growth and replication of mature organoids
+

(Figure 3-15 B-E and J-M). I confirmed loss of Dnmt1 in 4OHT-treated, VillinCreERT2 organoids
by immunohistochemistry (Figure 3.15 F-I). Additionally, TUNEL staining demonstrated no
increase in apoptosis rate in the 4OHT-treated, Dnmt1-ablated mature organoids (Figure 3.15 NQ). These results support my hypothesis that Dnmt1 performs unique functions in the developing
intestinal epithelium, and plays a role in the establishment but not maintenance of crypts
postnatally.
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Discussion
Taken together, my RNA-Seq, immunostaining, and organoid data reveal a crucial role
for Dnmt1 in maintaining DNA methylation patterns, genomic stability, and progenitor cell status
during intestinal development in vivo. I observed significant genome-wide DNA demethylation by
targeted bisulfite sequencing of the LINE1 locus and the H19 ICR (Figure 3.3 G-H). My RNA-Seq
and immunostaining data demonstrate that Dnmt1-deficient progenitors express decreased levels
of genes essential for mitosis and chromosome segregation (Table 3.1 and Figure 3.7 C), and
have increased rates of double-strand breaks (Figure 3.10 D-F). An increased rate of doublestrand breaks during the S-Phase of the cell cycle activates the G1/S checkpoint, mediated by
p53 and p21. Indeed, increased p21 expression in the Dnmt1-deficient epithelium indicates that
this checkpoint is active in mutant cells (Figures 3.10 G-H and 3.6 D). However, downstream
targets of the DNA damage response pathway, including Atm, Chek2, and Mlh1, exhibit
decreased expression by RNA-Seq (Table 3-1 and Figure 3.6 C), suggesting that Dnmt1-deficient
intestinal progenitor cells are unable to activate the normal response to accumulated DNA
damage. As a result, these Dnmt1-deficient progenitors undergo apoptosis, which leads to global
loss of the intestinal epithelium (Figure 3.10 A-C). These findings are supported by previous
studies implicating a requirement for Dnmt1 in DNA replication (Knox, Araujo et al. 2000), the
DNA damage response (Mortusewicz, Schermelleh et al. 2005, Unterberger, Andrews et al. 2006,
Loughery, Dunne et al. 2011), and cell cycle arrest (Chen, Hevi et al. 2007).
My results demonstrate an essential role for Dnmt1 in maintaining epithelial genomic
integrity during perinatal intestinal development. Interestingly, when I ablated Dnmt1 in the adult
intestinal epithelium using a tamoxifen-inducible VillinCreERT2 transgene, I did not see a
requirement for Dnmt1 in crypt cell survival, despite demethylation at the LINE1 locus (Figure
3.12 A) (Sheaffer, Kim et al. 2014). These opposing phenotypes raise several questions. It is
possible that in the adult intestinal epithelium, loss of Dnmt1 protein is compensated for by the de
novo methyltransferases Dnmt3a and Dnmt3b. Alternatively, the unique requirement for Dnmt1 in
newborn mice may be due to the significantly increased replication rate of neonatal progenitors
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compared to adult crypt cells (Itzkovitz, Blat et al. 2012). As shown in Figure 3.13, the neonatal
intestinal epithelium displays twice the fractional proliferation rate than that of adult mice. Thus, I
hypothesize that as the neonatal Dnmt1-ablated cells divide their DNA methylation levels are
rapidly reduced, and Dnmt3a and Dnmt3b do not compensate this loss. The high rate of
proliferation in the neonatal intestine also distinguishes these findings concerning the developing
intestine from studies of neuroblasts (Fan, Beard et al. 2001) or embryonic pancreas (Georgia,
Kanji et al. 2013).
Another possibility to explain the diverging phenotypes of adult and neonatal intestinal
Dnmt1-ablation is that DNA methylation might not be crucial for cell survival and function in the
mature crypt architecture. This explanation is supported by our organoid culture experiments
(Figures 3.10 G-N, 3.14, and 3.15). The perinatal Dnmt1-deficient intestine fails to successfully
produce organoids, in contrast to littermate controls (Figure 3.10 G-N). To test the differing
requirements for Dnmt1 during organoid crypt development and maintenance, I used the
inducible Dnmt1

loxP/loxP

;VillinCreERT2 system (Sheaffer, Kim et al. 2014). When Dnmt1 was

ablated before budding structures appear, organoids failed to thrive and eventually died (Figure
3.14). However, ablation of Dnmt1 after organoid buds and the ISC niche are established had
little effect on the maintenance of replicating progenitors (Figure 3.15).
Several recently published studies analyze the differences between fetal progenitors and
adult ISCs (Fordham, Yui et al. 2013, Mustata, Vasile et al. 2013). Fordham and colleagues
report that intestinal progenitor cell maturation correlates with increased Wnt signaling. In their
study, Lgr5

+

cells isolated from neonatal intestine produced budding organoids, with high
-

expression of adult stem cell markers. Lgr5 cells isolated from the same neonatal tissue formed
fetal enterospheres (FENs), which expressed low levels of Wnt factors and ISC markers, and did
not display budding activity. My results strongly support the notion that adult and perinatal
intestinal progenitors are not equivalent populations, and have differential requirements for cell
maintenance.
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In conclusion, I have demonstrated an important role for Dnmt1 in establishing intestinal
epithelial crypts following birth. I suggest that Dnmt1 is essential during the first few weeks of life
to maintain genomic methylation patterns during this period of intense cellular proliferation and
villus growth, and to prevent genome alterations that lead to progenitor cell death. Future
research in this field should focus on the varying requirements for DNA methylation during
development, particularly in supporting genomic stability and proliferation during organ
development, in contrast to those necessary in adulthood.
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Figure 3.1. Time course of Dnmt1 localization during intestinal epithelial development.
(A-D) Dnmt1 is expressed in the intervillus regions during late fetal development, and becomes
restricted to crypts in the adult intestine. Dnmt1 protein stain is brown; hematoxylin nuclear
counterstain is blue. Scale bars are 50 µm.
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Figure 3.2. Embryonic Dnmt1
while the adult Dnmt1

loxP/loxP

loxP/loxP

;VillinCre intestine is highly mosaic for Dnmt1 ablation,

;VillinCre is repopulated by cells that have escaped Cre-

mediated Dnmt1 ablation.
(A-C) E18.5 mutants showed variable levels of Dnmt1-ablation, with the majority of intervillus
regions retaining expression of Dnmt1 protein (B,C). (D,E) Dnmt1 immunohistochemistry in
controls and mutants at 3 months of age revealed that mutant intestines are predominantly
+

Dnmt1 . Scale bars are 50 µm.
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Figure 3.3. Ablation of Dnmt1 in the developing intestinal epithelium causes reduced
proliferation and DNA hypomethylation.
(A) Only 35% of Dnmt1

loxP/loxP

;VillinCre mutants survived to postnatal day 20 (P20) (n=14). (B) P0

mutants have significantly fewer villi relative to littermate controls (n=4). (C,E) Dnmt1 protein
immunohistochemistry, (D,F) Ki67 protein immunohistochemistry. P0 mutants display mosaic
Dnmt1 ablation compared to controls (C,E). Absence of Dnmt1 (E, red brackets) corresponds to
loss of proliferation in mutant progenitors as assessed by Ki67 staining of adjacent section (F, red
+

brackets). Dnmt1 progenitors show similar proliferation in mutants (black bars E,F) compared to
controls (D). (G) LINE1 repeat DNA methylation levels as assessed by bisulfite-sequencing (n=4).
Decreased LINE1 methylation indicates global demethylation in Dnmt1 mutant progenitor cells
compared to controls. (H) H19 imprinting control region (ICR) DNA methylation levels are
decreased in mutant progenitor cells relative to controls (n=4). For all graphs, data are
represented as mean ± SEM. *P<0.05; **P<0.01; ***P<0.001, two-tailed Student’s t-test. Scale
bars are 50 µm.
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Figure 3.4. Dnmt3a and Dnmt3b are not upregulated in Dnmt1

loxP/loxP

;VillinCre neonatal

mutants.
(A,B) Immunohistochemistry for Dnmt1 in Dnmt1

loxP/loxP

controls and Dnmt1

loxP/loxP

;VillinCre

mutants. (C) qRT-PCR of whole neonatal proximal jejunum showed a significant decrease in
Dnmt1 transcript in mutants compared to littermate controls. (D-E,G-H) Immunostaining on serial
sections demonstrated no change in Dnmt3a (green, second row) and Dnmt3b (red, third row)
localization. (F,I) qRT-PCR does not reveal a significant difference in Dnmt3a or Dnmt3b gene
expression. In all images, scale bars are 50 µm. For all qRT-PCR, control n=10, mutant n=12.
Data are represented as mean ± SEM. ***P<0.001, two-tailed Student’s t-test.
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Figure 3.5. Dnmt1 and Ki67 protein are co-localized in the intervillus progenitor zone.
(A-D) Co-staining for Dnmt1 (A,B) and Ki67 (C,D) using separate imaging of each protein on the
same section revealed strong overlap of Dnmt1 and Ki67 proteins in controls (A,C).
Dnmt1

loxP/loxP

;VillinCre epithelial cells with Dnmt1 ablation (B), do not express Ki67 (D). In all

images, scale bars are 50 µm.
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Figure

3.6.

Collection

of

Dnmt1-ablated

progenitors

cells

by

Laser

Capture

Microdissection (LCM).
(A) Gene expression levels of Dnmt3a, Dnmt3b, and mKi67 from RNA-Seq data. Fold change is
relative to control. (B) RNA-Seq expression of Dnmt1 exon 5, which is excised upon Cre
activation, indicates a nearly 90% reduction in Dnmt1 mRNA levels in the LCM tissue of
Dnmt1

loxP/loxP

;VillinCre compared to controls (RPM, Reads per Million). (C,D) We performed

additional LCM to confirm RNA-Seq data in independent biological replicates (Dnmt1
controls, n=4; Dnmt1

loxP/loxP

loxP/loxP

;VillinCre mutants, n=3). (C) qRT-PCR confirmation of genes that are

misregulated in RNA-Seq data: Dnmt1, Chek2, Atm, Mcm10, Cdk2, Mlh1, Foxm1, and Lyz. (D)
Validation of p21 expression levels, which is upregulated in our RNA-Seq data. qRT-PCR data
are presented normalized to the geometric mean of 5 reference genes: Tbp, B2m, β-actin, Polr2b,
and Rplp0. (B-D) Data are represented as mean ± SEM. *P<0.05, **P<0.01, one-tailed Student’s
t-test.
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Figure 3.7. RNA-Seq analysis reveals decreased expression of crucial cell-cycle regulators
in Dnmt1-deficient progenitor cells.
(A, B) Collection of intervillus regions (encircled) before (A) and after (B) laser capture
microdissection (LCM). (C) DAVID gene ontology analysis of genes with transcripts are
downregulated in Dnmt1-deficient epithelial cells as determined by RNA-Seq. (D,E) Co-staining
for Ki67 (green) and lysozyme (red) in control and Dnmt1 mutant intestine. A fraction of nonreplicating Dnmt1-negative cells exhibit increased lysozyme protein levels (E, arrows), a marker
for Paneth cell differentiation, relative to controls (D). (F,G) Immunohistochemistry (IHC) showing
that in controls p21 protein is confined to differentiated cells in the villus; in Dnmt1 mutants,
expression is strikingly increased in intervillus regions (black bracket in F versus red bracket in
G). (H,I) Dnmt1 immunohistochemistry on serial sections confirms Dnmt1 ablation in cells
indicated by red brackets in G,I. In all images, scale bars are 50 µm.
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Table 3.1. Genes differentially expressed between Dnmt1

loxP/loxP

;VillinCre and Dnmt1

loxP/+

intestine.
RNA-Seq data from LCM tissue for genes of interest. Fold change indicates expression levels
relative to control. FDR<0.1.
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Figure 3.8. Enterocyte, enteroendocrine, Paneth, and goblet cell populations in
Dnmt1

loxP/loxP

;VillinCre mutants.

(A-B, E-F, I-J, M-N) Dnmt1 immunohistochemistry on serial sections confirms loss of Dnmt1 in
the mutant regions analyzed. (A-D) Alkaline phosphatase (AP) staining for absorptive enterocytes
revealed a small increase in AP+ mutant progenitor cells (black arrowheads in D) relative to
controls (C). (E-H) Chromogranin A (ChgA) staining for enteroendocrine cells revealed a small
increase in ChgA+ progenitor cells in mutants (H, white arrow) compared to controls (G). (I-L) Costaining for Ki67 (green) and lysozyme (red) in control and Dnmt1 mutant intestine. Nonreplicating Dnmt1-mutant progenitors had increased lysozyme protein (L, white arrows), a marker
for Paneth cell differentiation, relative to controls (K). (M-P) Mucin2 staining showed similar
staining patterns of goblet cells in control (O, circled cells) and Dnmt1 mutant (P, circled cells)
progenitor zones. In all images, scale bars are 50 µm.
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Figure 3.9. Key DNA damage response genes are significantly demethylated in Dnmt1ablated perinatal intestinal epithelial progenitors.
(A-D) Targeted bisulfite-sequencing analysis of DNA damage response genes demonstrates
significant demethylation upstream of p21 (A), Chek2 (B), Atm (C), and Mlh1 (D) in
Dnmt1

loxP/loxP

;VillinCre mutants compared to littermate controls. Beneath each bar chart is a

diagram indicating the position of the transcription start site (TSS, arrow) and CpG islands relative
to the regions sequenced. Each region is ~2-4 kb upstream of the TSS. For all graphs, error bars
are ± SEM, **P<0.01, ***P<0.001, two-tailed Student’s t-test.
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Figure 3.10. Ablation of Dnmt1 in the immature intestine results in loss of progenitor cells
via apoptosis both in vivo and in vitro.
(A,B) TUNEL staining in red, E-cadherin in green, DAPI in blue. TUNEL staining demonstrates
increased levels of apoptosis in Dnmt1 mutant progenitor cells (A) compared to control (B). (C)
TUNEL-positive intervillus nuclei within 20 µm from the epithelial base (red vertical bars in A,B)
were quantified in Dnmt1 mutants and littermate controls (n≥5). (D-F) Dnmt1 mutant progenitors
(E) have increased DNA double strand breaks compared to controls (D), as determined by
+

+

γH2AX staining. (F) Quantification of γH2AX cell number as performed for TUNEL cells (n=4); 20
µm vertical bar shown in (D,E). (G) Experimental outline for postnatal day 1 (P1) Dnmt1
(n=3) and Dnmt1

loxP/loxP

loxP/loxP

;VillinCre (n=2) intestinal organoid cultures. (H) Average number of

organoids per well during timecourse experiment. Organoids were grown in triplicate for each
biological
Dnmt1

replicate.

loxP/loxP

(I-N)

Live

phase

contrast

imaging

of

Dnmt1

loxP/loxP

control

and

;VillinCre mutant organoids on each day of culture. Surviving mutant organoids on

day 5 persisted as very small cysts (N), while controls were considerably larger and exhibited
budding activity (M). Phase contrast images were all captured at 10X. For all graphs, error bars
are ± SEM. *P<0.05, **P<0.01, ***P<0.001, two-tailed (C,F) or one-tailed (H) Student’s t-test.
Scale bars are 50 µm.
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Figure 3.11. Apoptosis and DNA damage in Dnmt1

loxP/loxP

;VillinCre mutant mice are

confined to the non-replicating intervillus epithelium.
(A-F) Co-staining for Ki67 (green, A,D) with TUNEL (red, B,E) in control (A-C) and Dnmt1mutants (D-F). Mutant progenitor zones harbor TUNEL+ apoptotic cells that correspond with
Ki67-negative non-proliferative regions (D-F). (G-M) γH2AX co-stained with Ki67 revealed that
control epithelium does not contain DNA-damaged cells in the progenitor zone (G-I). Ki67negative, mutant progenitors cells have increased levels of DNA damage (J-L). Scale bars are 50
µm.
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Figure 3.12. Dnmt1

loxP/loxP

;VillinCreERT2 adult crypt epithelial cells are demethylated at the

LINE1 locus, but not at DNA damage response genes.
(A) LINE1 repeat DNA methylation levels as assessed by bisulfite-sequencing. Decreased LINE1
methylation suggests global demethylation in Dnmt1-ablated adult crypt cells relative to controls.
(B) In the H19 imprinting control region (ICR), DNA methylation levels are slightly decreased in
adult Dnmt1-mutant crypt cells relative to controls. (C-F) Targeted bisulfite-sequencing analysis of
DNA damage response genes revealed similar levels of DNA methylation in adult Dnmt1-ablated
crypt cells compared to controls. (C,D) p21 (Cdkn1a) and Chek2 are not differentially methylated
in adult Dnmt1-mutant crypts. Atm (E) and Mlh1 (F) show an overall decrease in DNA methylation
relative to control, but are not significantly altered at each CpG analyzed. Beneath bar charts (CF) is a diagram indicating the position of the transcription start site (TSS, arrow) and CpG islands
relative to the regions sequenced. Each region is ~2-4 kb upstream of the TSS. Mutant n=5;
Control n=2. Data are represented as mean ± SEM, **P<0.01, ***P<0.001, two-tailed Student’s ttest.
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Figure 3.13. Neonatal intervillus regions display increased rate of replication compared to
adult crypts.
(A,B) Representative images of adult (A, n=5) and postnatal day 0 (B, n=12) jejunum stain for
+

EdU following a 2-hour EdU pulse (red). (C) Percent of EdU cells per crypt-villus subunit is
approximately two-fold higher in the neonatal compared to the adult jejunum. Rates calculated as
+

percent EdU nuclei of total nuclei between two adjacent villi peaks. Scale bars are 50 µm. Data
are represented as mean ± SEM. ***P<0.001, two-tailed Student’s t-test.
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Figure 3.14. Dnmt1 is required to establish intestinal organoid cultures.
(A)

Time

Dnmt1

loxP/loxP

course

of

4OHT

treatment

in

organoids

from

Dnmt1

loxP/loxP

and

;VillinCreERT2 adult intestine to test the requirement for Dnmt1 in establishment of

intestinal crypts in vitro. (B-Q) Immunohistochemical analysis of organoids described in (A). (B-E)
Live phase contrast imaging demonstrates reduced size and budding activity of Dnmt1-ablated
organoids (E) compared to controls (B-D). All phase contrast images were captured at 10X. (F-I)
Dnmt1 protein is reduced in Dnmt1

loxP/loxP

;VillinCreERT2 organoids upon treatment with 4OHT (I),

relative to control organoids (F-G). (J-M) 2 hour EdU treatment shows reduced replication rate of
Dnmt1-mutant organoids (M) compared to controls (J-L). (N-Q) Dnmt1-ablated organoids (Q)
display increased apoptosis (white arrowheads) relative to non-treated controls (N,P).
Additionally, apoptosis is not increased in control Dnmt1

loxP/loxP

organoids treated with 4OHT (O).

All scale bars are 50 µm.
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Figure 3.15. Dnmt1 is not necessary to maintain established intestinal organoid cultures.
(A) Time course of 4OHT treatment to test requirement for Dnmt1 in maintenance of intestinal
crypts in vitro. (B-Q) Immunohistochemical analysis of organoids described in (A). (B-E) Live
phase contrast imaging demonstrates similar size of Dnmt1-ablated organoids (E) at day 9 of
culture relative to 4OHT-treated (C) and non-treated (B,D) controls. All phase contrast images
were captured at 10X. (F-I) Confirmation of Dnmt1 protein depletion in 4OHT-treated
Dnmt1

loxP/loxP

;VillinCreERT2 organoids (I) compared to controls (F-H). (J-M) A 2-hour pulse of

EdU reveals preserved replication of Dnmt1-mutant organoids (M), similar to that observed in
control organoids (J-L). (E,I) Dnmt1-ablated organoids do not display any changes in apoptosis
(Q) compared to treated (O) or non-treated (N,P) control organoids. TUNEL positive material in
(P,Q) is typical debris accumulation within organoids. All scale bars are 50 µm.
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Chapter 4

Dnmt1 and Dnmt3b are required for genomic stability in
intestinal epithelial homeostasis
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Abstract
Colorectal cancer (CRC) is a heterogeneous disease accompanied by a sequence of
genetic mutations and epigenetic changes. DNA methylation is thought to drive CRC progression
by the repression of tumor suppressor genes via promoter methylation. The DNA
methyltransferase Dnmt1 is required for appropriate expression of stem cell genes and
differentiation of the intestinal epithelium. Using temporally controlled intestinal epithelial-specific
gene ablation, I show that loss of Dnmt1 in the Apc

Min/+

mouse model of intestinal cancer

surprisingly causes accelerated, not delayed, adenoma formation. Loss of Dnmt1 precipitates an
acute response characterized by hypomethylation of repetitive elements, genomic instability, and
apoptosis, which is followed by remethylation with time. This recovery is entirely dependent on
the activity of the de novo methyltransferase Dnmt3b. In light of these data, the current dogma
regarding the role of DNA methylation in colon cancer needs to be revisited.
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Introduction
Colorectal cancer (CRC) is a multifactorial disease with various inputs including diet,
environment, genetic mutations, and epigenetic abnormalities. The disease first manifests as an
over-proliferation defect in the form of polyps that, if not removed, can progress to precancerous
adenomas. Further transition to invasive and metastatic cancer is due to the accumulation of
multiple genetic mutations and epigenetic changes that alter gene expression patterns, driving
neoplastic transformation and growth (Fearon 2011). However, the extent to which epigenetic
modifications, and specifically DNA methylation, contribute to the initiation and progression of
CRC is unclear.
DNA methylation patterns are established by DNA methyltransferase enzymes (Dnmts),
of which there are two categories. The ‘maintenance’ methyltransferase, Dnmt1, has a high
affinity for hemi-methylated DNA in vitro, and preserves DNA methylation in replicating cells. The
‘de novo’ methyltransferases, Dnmt3a and Dnm3b, establish novel patterns of DNA methylation,
and prefer to bind unmethylated DNA in vitro. DNA methylation is generally found in the context
of CpG dinucleotides in mammals, and while most of the genome is highly methylated, promoter
and distal regulatory regions display low levels of DNA methylation (Stadler, Murr et al. 2011,
Ziller, Gu et al. 2013, Sheaffer, Kim et al. 2014). Regulatory regions also exhibit the most
dynamic DNA methylation among distinct tissue types, and are commonly hypomethylated in
cancer (Irizarry, Ladd-Acosta et al. 2009, Stadler, Murr et al. 2011, Ziller, Gu et al. 2013).
Comparison of human colon adenomas to control tissue revealed that although proximal
promoter CpG islands are generally hypermethylated in tumors, DNA hypomethylation is found
genome-wide, including at neighboring CpG island shores, intergenic regions, and repetitive
elements (Berman, Weisenberger et al. 2012, Luo, Wong et al. 2014).
DNA methylation is critical for intestinal epithelial homeostasis (Sheaffer, Kim et al. 2014,
Elliott, Sheaffer et al. 2015). Intestinal stem cells are located in the crypt and respond to multiple
signaling pathways that control proliferation and differentiation (Sheaffer and Kaestner 2012).
Loss of Dnmt1 in the mouse intestine causes hypomethylation of regulatory regions associated
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with several intestinal stem cell genes, resulting in inappropriate activation during differentiation,
and expansion of the crypt zone (Sheaffer, Kim et al. 2014). Many intestinal stem cell factor
genes, such as LGR5, OLFM4, and HES1, are also highly expressed in human colon cancer (van
der Flier, Haegebarth et al. 2009, Chen, Zhang et al. 2014, Gao, Zhang et al. 2014). These data
suggest that DNA hypomethylation may play an important role in intestinal cancer progression.
Previously, the role of Dnmt1 in intestinal tumorigenesis was studied in the Apc

Min/+

mouse model. This paradigm mimics the hereditary human colon cancer syndrome Familial
Adenomatous Polyposis (FAP), which is caused by germline mutations of the APC gene (Su,
Kinzler et al. 1992). Loss of heterozygosity (LOH) at the APC locus causes β-catenin stabilization
and unrestricted Wnt activity, resulting in the formation of microadenomas, which progress to
large adenomas over time. Multiple hypomorphic Dnmt1 paradigms show complete block of
macroscopic tumor formation (Laird, Jackson-Grusby et al. 1995, Cormier and Dove 2000, Eads,
Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, Jackson-Grusby et al. 2005). The authors
concluded that Dnmt1 and DNA methylation are required for adenoma development in the
Apc

Min/+

model. These studies employed hypomorphic Dnmt1 mice, which express constitutively

reduced Dnmt1 levels from earliest development onward in all tissues (Laird, Jackson-Grusby et
al. 1995), including non-epithelial cells, such as myofibroblasts. Mesenchymally expressed genes
have been shown to be strong modifiers of the Apc

Min/+

tumor load (Perreault, Sackett et al. 2005),

and could thus contribute to the observed phenotype in the Dnmt1-hypomorphic Apc

Min/+

intestine.

Due to these limitations, the precise mechanism of how DNA methylation acts within the intestinal
epithelium during adenoma initiation and progression remains to be determined.
To address this important knowledge gap, I employed a temporally controlled, intestinal
epithelial-specific gene ablation model to delete Dnmt1 and decrease maintenance DNA
methylation. I find that deletion of Dnmt1 causes accelerated loss of heterozygosity at the Apc
locus, with a dramatic increase in adenoma initiation and progression. Ablation of Dnmt1 causes
a severe acute phenotype characterized by global DNA hypomethylation, genome instability, and
apoptosis. Contrary to the current dogma, I demonstrate that the de novo methyltransferase
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Dnmt3b is essential for epithelial recovery following Dnmt1 ablation, and provide evidence that
Dnmt3b compensates for the maintenance methyltransferase in vivo.
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Results
Deletion of Dnmt1 in the intestinal epithelium of adult Apc

Min/+

mice accelerates adenoma

initiation.
To determine the role of Dnmt1 in intestinal adenoma formation, I employed
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice to inducibly delete Dnmt1 throughout the intestinal and

colonic epithelia. Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice and their Apc

Min/+

;Dnmt1

loxP/loxP

siblings were injected with tamoxifen to induce Dnmt1 deletion at four weeks of age (see
experimental schema in Figure 4.1). At three months of age, the small intestine and colon were
examined for neoplastic transformation. Dnmt1 deletion was effective throughout the mutant
epithelia of small intestine and colon (Figures 4.2 A,B and 4.3 A,B). Surprisingly, hematoxylin and
eosin staining revealed a dramatic increase in the number of neoplastic lesions throughout the
entire Dnmt1-deficient small intestine, where mutants displayed >6-fold more macroscopic
adenomas (Figure 4.2 C-E).
Previously, it had been reported that partial loss of Dnmt1 produces a block in the
progression of adenomas in the Apc

Min/+

mouse paradigm (Laird, Jackson-Grusby et al. 1995,

Cormier and Dove 2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, JacksonGrusby et al. 2005), which is in sharp contrast to our finding of an increased number of
macroscopic lesions in the Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 deletion model. To confirm that

these lesions are bona fide adenomas, I performed histopathologic assessment on the intestines
of three-month old Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 and Apc

Min/+

;Dnmt1

loxP/loxP

mice which had

been tamoxifen treated at 4 weeks of age. Using criteria described by Biovin et al. (2003), I found
15-fold more lesions that had progressed to adenomas in Dnmt1-deficient mice as compared to
Apc

Min/+

animals (Figure 4.2 F). In addition, Dnmt1-deficient small intestinal tumors were on

average twice as large as those of controls (Figure 4.2 G).
Adenoma formation in the Apc

Min/+

mouse model is driven by loss of heterozygosity (LOH)

at the Apc locus, which causes nuclear accumulation of β-catenin and activation of Wnt signaling.
LOH is observed in virtually all Apc

	
  

Min/+

intestinal tumors (Levy, Smith et al. 1994, Luongo, Moser
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et al. 1994). Thus, increased tumor load likely reflects accelerated LOH at earlier time points. To
establish if increased macroadenoma formation in three-month old Dnmt1-mutants correlated
with earlier tumor initiation, I injected four-week old Apc
(mutant) and their Apc

Min/+

;Dnmt1

loxP/loxP

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice

(control) siblings with tamoxifen, and examined the small

intestine at two months of age for microadenomas (see schema in Figure 4.1). Mutant animals
displayed an increase in microadenoma number in the small intestine compared to controls
(Figure 4.2 H), even though lesions were still comparable in size (Figure 4.2 G). All lesions
observed in two-month old animals showed similar histopathology and were characterized as
gastrointestinal intraepithelial neoplasias (data not shown).
Previous studies also reported increased colonic microadenomas in Dnmt1-hypomorphic
Apc

Min/+

mice (Yamada, Jackson-Grusby et al. 2005). To investigate microadenoma formation in

the colon, I employed nuclear β-catenin staining to identify neoplastic lesions in three-month old
mice. Only 14% of control mice displayed neoplastic transformation in the colon (n=7). However,
58% of Dnmt1-deficient Apc

Min/+

colons (n=12) showed at least one incidence of microadenoma,

including several mice with multiple lesions (Figure 4.3 D). Since Apc

Min/+

mice exhibit tumors

predominantly in the small intestine (Moser, Pitot et al. 1990, Moser, Dove et al. 1992), I focused
my studies on adenoma development and progression in the small intestinal epithelium.
To characterize adenoma initiation by LOH in detail, I employed laser capture
microdissection to isolate neoplastic and normal intestinal epithelial cells in tamoxifen-treated
twoApc

and

Min/+

three-month

;Dnmt1

loxP/loxP

old

Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2

mutant

mice

and

their

control siblings. DNA was isolated from these samples (approximately

1,000 cells per sample) and the status of the Apc alleles was examined as performed previously
(Luongo, Moser et al. 1994). Analysis of control and mutant mice produced bands for both the
wildtype Apc and the Apc

Min

lesions showed only the Apc

Min

alleles in the normal epithelium, as expected, while neoplastic
allele band (data not shown).

Several lines of evidence confirm that the numerous adenomas that develop in the
Dnmt1-deficient

	
  

Apc

Min/+

mice

are

the

result

	
  

of

Wnt

pathway

activation.

Thus,
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Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 (mutant) adenomas showed increased nuclear β-catenin

protein (Figure 4.4 B,C), and multiple Wnt signaling targets, such as CycD1 (Figure 4.4 E,F) and
Sox9 (Figure 4.4 H,I) were also strongly activated. These data demonstrate that total loss of
Dnmt1 in the mature small intestinal epithelium promotes neoplastic progression, in stark contrast
to what had been reported previously (Laird, Jackson-Grusby et al. 1995, Cormier and Dove
2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, Jackson-Grusby et al. 2005).

Dnmt1-null adenomas display increased chromosome instability
Due to the dramatic difference in lesion size and grade observed in three-month old
animals, I investigated whether Dnmt1-deficiency had any impact on cell proliferation or death in
Apc

Min/+

Apc

Min/+

adenomas.
;Dnmt1

loxP/loxP

I

analyzed

Apc

Min/+

;Dnmt1

loxP/loxP

(control)

and

;VillinCreERT2 (mutant) tumor proliferation using the cell cycle marker, Ki67

(Figure 4.5 B-D). Non-tumor Dnmt1-deficient intestinal epithelium displayed a slight expansion of
the crypt zone, as reported previously (Sheaffer, Kim et al. 2014). I also determined the
percentages of control and mutant epithelial cells in M-phase by staining for phosphorylated-H3
(PH3) (Figure 4.5 A). These data show that the proliferation rate was equivalent in Dnmt1-positive
or -negative tumors, at both two months and three months of age. Furthermore, comparison of
three-month old control and two-month old mutant adenomas revealed that similarly sized tumors
had comparable rates of cellular proliferation (Figure 4.5 B,C). I also examined neoplastic cells for
signs of cell death using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL),
which detects DNA fragmentation in apoptotic cells. Both control and mutant adenomas exhibited
only rare epithelial cells positive for TUNEL, and I found no difference in cell death between
Dnmt1-mutant and control neoplastic epithelia. However, many subepithelial cells were TUNEL
positive (Figure 4.5 E-G). These data demonstrate that loss of Dnmt1 in vivo has no effect on
Apc

Min/+

adenoma proliferation or cell death, and indicates that the increase in adenoma number

and size found in three-month old Dnmt1-mutant mice is driven by accelerated tumor initiation
through loss of heterozygosity.
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I next investigated the requirement of Dnmt1 for chromosome stability in our intestinal
cancer model. Global DNA hypomethylation correlates with chromosomal instability in CRC
(Lengauer, Kinzler et al. 1997, Rodriguez, Frigola et al. 2006). I employed γH2AX staining to
visualize DNA double-strand breaks as a marker of chromosomal instability, and found many
more epithelial cells within Dnmt1-deficient adenomas to be γH2AX

+

compared to control

adenomas (Figure 4.5 H-J). Notably, γH2AX foci had already appeared in two-month old mutant
adenomas that are of similar size to control three-month old adenomas (Figure 4.5 H,I). These
data indicate that increased double strand breaks are not simply the consequence of rapid tumor
growth, but an early event in tumorigenesis in the Dnmt1-deficient Apc

Dnmt1 deletion in Apc

Min/+

Min/+

mouse.

mice causes massive epithelial remodeling within one week

To determine the underlying causes of accelerated loss of heterozygosity and increased
tumorigenesis in the Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutant intestine, I next focused on the

earliest events following Dnmt1 ablation. To this end, I injected tamoxifen in four-week old
Apc

Min/+

Dnmt1

;Dnmt1

loxP/loxP

loxP/loxP

;VillinCreERT2

mice

;VillinCreERT2, and Dnmt1

(mutant)

loxP/loxP

and

their

Apc

Min/+

;Dnmt1

loxP/loxP

,

siblings (controls), and examined the small

intestine one week later (see Figure 4.1 for experimental schema). I confirmed loss of Dnmt1
protein (Figure 4.6 E-H), and proceeded to gross histological analysis. Acute loss of Dnmt1 in
Dnmt1

loxP/loxP

as

described

Apc

Min/+

;VillinCreERT2 mice caused crypt expansion compared to controls (Figure 4.6 A-B),

;Dnmt1

previously

loxP/loxP

(Sheaffer,

Kim

et

al.

2014).

Although

the

;VillinCreERT2 mutant intestine exhibited crypt expansion, surprisingly, I

also detected many areas that displayed a drastic loss of crypt and villus epithelium (Figure 4.6
C-D). When I assessed proliferation by performing immunofluorescent staining for Ki67, the
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutant intestine contained many crypts that had little to no

Ki67 staining (compare Figure 4.6 L to 4.6 K), while crypts in Dnmt1

loxP/loxP

;VillinCreERT2

intestine had an obvious increase in the proliferative zone (Figure 4.6 I-J). Additionally, I
performed TUNEL staining to assess levels of apoptosis in Apc

	
  

	
  

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2
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mutants and control siblings (Figure 4.6 M-P). Interestingly, I observed increased levels of crypt
cell apoptosis in Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 (Figure 4.6 P) relative to all other conditions.

These data indicate that loss of Dnmt1 on the Apc

Min/+

background causes a severe acute

+/+

phenotype of crypt loss not present in the Apc , Dnmt1-deficient intestine.
Apc

Min/+

mice display increased sensitivity to DNA damage, including damage induced by

ionizing radiation (Tao, Tang et al. 2015), and are also noted to have defects in epithelial cell
migration (Mahmoud, Boolbol et al. 1997). I reasoned that loss of Dnmt1 might induce genome
instability that many epithelial cells in Apc

Min/+

mice are unable to repair. To determine basal levels

of DNA damage in mice one week after tamoxifen administration, long before tumor formation
has been initiated, I performed γH2AX staining (Figure 4.6 I-L). I discovered a dramatic increase
+

in the fraction of γH2AX crypt cells in Apc
Apc

Min/+

Min/+

;Dnmt1

controls, which contained no γH2AX

demonstrate that genomic instability in Apc
accelerated tumorigenesis. Dnmt1

loxP/loxP

+

Min/+

loxP/loxP

;VillinCreERT2 (Figure 4.6 L) versus

epithelial cells (Figure 4.6 K). These results

;Dnmt1

loxP/loxP

;VillinCreERT2 mice occurs prior to

;VillinCreERT2 mutants also displayed low levels of

+

γH2AX crypt cells, indicating that Dnmt1 is required to maintain genomic stability in proliferating
intestinal cells (Figure 4.6 I,J).

DNA methylation dynamics following Dnmt1 deletion
Despite the striking acute phenotype I observed following Dnmt1 deletion in the adult
Apc

Min/+

intestinal epithelium, Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutant mice survive to three

months of age. I hypothesized that the dramatic loss of global DNA methylation following Dnmt1
ablation precipitates acute genome instability, and that animal survival to three months correlates
with recovery of DNA methylation levels. To test this hypothesis, I performed targeted bisulfite
sequencing of the Long Interspersed Nucleotide Element 1 (LINE1) to estimate global DNA
methylation levels, and of the H19 imprinting control region (ICR) to determine DNA methylation
maintenance (Lane, Dean et al. 2003, Yang, Estécio et al. 2004, Samuel, Suzuki et al. 2009).
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I
Apc

Min/+

employed

;Dnmt1

loxP/loxP

laser

capture

microdissection

;VillinCreERT2 mutant and Apc

Min/+

;Dnmt1

to

collect

loxP/loxP

crypts

from

control intestines one week

following tamoxifen treatment (see schema in Figure 4.1). Strikingly, within one week following
Dnmt1 deletion, I observed a 50% reduction in DNA methylation at the LINE1 loci in mutant
crypts compared to control crypt epithelium (Figure 4.7 A). In contrast, methylation of the H19
imprinting control region was maintained, indicating that maintenance methylation of imprinted
loci was preserved in Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 intestinal epithelium (Figure 4.8 A).

To assess recovery of global DNA methylation with time, I implemented laser capture
microdissection
Apc

Min/+

;Dnmt1

to

loxP/loxP

isolate

the

neoplastic

and

;VillinCreERT2 mutant and Apc

Min/+

normal
;Dnmt1

intestinal

loxP/loxP

epithelia

from

control intestines at three

months of age, two months after tamoxifen administration. Surprisingly, I found no differences in
methylation levels in all conditions tested, demonstrating that DNA methylation had been fully
restored after acute loss following Dnmt1 ablation (Figure 4.7 B). I excluded the trivial explanation
that Dnmt1-positive ‘Cre-escaper’ cells had repopulated the neoplastic epithelium by performing
immunohistochemistry for Dnmt1 protein, confirming that these tumors were Dnmt1-negative
(compare Figure 4.9 B to 4.9 A).
I surmised that the de novo methyltransferases might compensate for the loss of Dnmt1,
and performed immunofluorescent staining for both Dnmt3a and Dnmt3b one week following
Dnmt1 deletion. While I observed no change in Dnmt3a levels by immunofluorescence (Figure
4.10
Apc

Min/+

A,B),
;Dnmt1

I
loxP/loxP

found

Dnmt3b

protein

levels

increased

in

five-week

old

;VillinCreERT2 crypts compared to sibling controls (Figure 4.10 C,D).

Overall, these data suggest a mechanism in which Dnmt3b is activated to compensate for loss of
Dnmt1 in the intestinal epithelium. I next aimed to test this proposed compensation mechanism
using mouse genetics.
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Dnmt3b is required to maintain DNA methylation and epithelial integrity in the absence of
Dnmt1
To directly test the requirement for Dnmt3b in maintaining DNA methylation in the
Apc

Min/+

;Dnmt1

Yamada

loxP/loxP

et

;VillinCreERT2 intestinal epithelium, I bred the Dnmt3b
al.

2006)

onto
;VillinCreERT2

Apc

Min/+

;Dnmt1

loxP/loxP

;Dnmt3b

loxP/loxP

Apc

Min/+

;Dnmt1

loxP/loxP

;Dnmt3b

loxP/loxP

the

mutant

loxP/loxP

genotype,

mice,

allele (Lin,
producing

along

with

siblings as controls. In these cohorts of mice, I injected

tamoxifen at four weeks of age to induce simultaneous ablation of Dnmt1 and Dnmt3b. I isolated
small intestines one week following tamoxifen administration for phenotypic analysis.
Histological
Apc

Min/+

examination

revealed

a

grossly

altered

epithelium

in

the

;Dnmt1;Dnmt3b mutant mice, with many areas lacking villi and/or crypts completely

(compare Figure 4.11 B to 4.11 A). I performed immunohistochemistry for Dnmt1 and Dnmt3b to
confirm loss of both proteins in the majority of the epithelium (Figure 4.11 C-F). Many crypts in
mutants were completely Ki67-negative (Figure 4.11 H), and harbored extensive DNA damage as
indicated by γH2AX foci (compare Figure 4.11 H versus 4.11 G). TUNEL staining revealed
increased crypt cell apoptosis in Apc

Min/+

;Dnmt1;Dnmt3b mutants compared to sibling controls

(Figure 4.11 J versus 4.11 I). Hyper-proliferative crypts often escaped Cre-mediated Dnmt3b
deletion (data not shown), consistent with my hypothesis that Dnmt3b is required to preserve
epithelial integrity in the absence of Dnmt1.
To assess the overall requirement for Dnmt3b in Apc
survival, I injected tamoxifen into groups of Apc

Min/+

;Dnmt1

Min/+

loxP/loxP

;Dnmt1

loxP/loxP

;VillinCreERT2

;Dnmt3b

loxP/loxP

;VillinCreERT2

mutants and littermate controls at four weeks of age, and weighed mice each day following
CreERT2 induction. All Apc

Min/+

;Dnmt1;Dnmt3b mutant mice became severely morbid within three

weeks following tamoxifen administration and had to be euthanized (Figure 4.11 K). In contrast,
96% of Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutant mice survived to three weeks following

tamoxifen injection (Figure 4.11 K), demonstrating that loss of Dnmt1 alone is non-lethal in the
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mature intestinal epithelium. I conclude that Dnmt3b is crucial for epithelial survival in the
Apc

	
  

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mouse model (Figure 4.12 G-I).
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Discussion
The results presented above have major implications for the fields of DNA methylation
and intestinal cancer biology. I show that loss of the DNA methyltransferase Dnmt1 in the Apc

Min/+

cancer model results in acute hypomethylation and DNA damage (see summary model in Figure
4.12). I posit that this decreased genomic stability accelerates loss of heterozygosity (LOH) at the
Apc locus, resulting in increased tumorigenesis and larger tumors (Figure 4.12 F). DNA
methylation has been linked to genomic instability in multiple contexts, in both cell lines and in
disease. In the HCT116 colorectal cancer cell line, ablation of catalytically active DNMT1 causes
cell cycle arrest and apoptosis due to increased chromosomal instability (Chen, Hevi et al. 2007,
Spada, Haemmer et al. 2007). Global hypomethylation in mice results in chromosome
duplications and invasive T-cell lymphomas at four months of age (Gaudet, Hodgson et al. 2003),
and in mouse ES cells, loss of Dnmt1 also causes global hypomethylation and increased
mutation rates (Chen, Pettersson et al. 1998). In mouse embryonic fibroblasts (MEFs), ablation of
Dnmt1 causes gradual hypomethylation, deregulated gene expression, and cell death (JacksonGrusby, Beard et al. 2001). My work adds to this body of evidence that implicates a crucial role
for Dnmt1 and DNA methylation in maintaining genome stability.
Importantly, my study shows increased intestinal adenoma formation after deletion of
Dnmt1. My experimental paradigm results in intestine-specific, temporal loss of Dnmt1 and acute
hypomethylation, followed by recovery of global genome DNA methylation, in contrast to prior
work, which had employed germline hypomorphic Dnmt1 alleles (Laird, Jackson-Grusby et al.
1995, Cormier and Dove 2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada,
Jackson-Grusby et al. 2005). These previous studies thus differed both in the timing of Dnmt1
deletion and in lack of tissue specificity. Early intestinal development requires Wnt signaling to a
lesser degree than the established adult stem cell niche (Korinek, Barker et al. 1998, Kim, Mao et
al. 2007, Mustata, Vasile et al. 2013). In addition, deletion of Dnmt1 during crypt establishment
has different consequences on global DNA methylation than ablation in mature crypts, and
causes cell death (Elliott, Sheaffer et al. 2015). Indeed, Laird and colleagues noted that tumor
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suppression in their model only occurred if hypomethylation was induced early in life (1995).
Therefore, deletion of Dnmt1 during crypt establishment may lead to decreased cell proliferation
and a decreased opportunity for tumor initiation. After crypts are established, ablation of Dnmt1
results in increased proliferation and decreased genome stability, causing accelerated loss of
Apc

Min/+

heterozygosity and adenoma formation (Figure 4.12 D-F).
Current dogma holds that deletion of Dnmt1 is lethal in all dividing somatic cells (Liao,

Karnik et al. 2015); however, I find that the rapidly dividing intestinal epithelium can survive
without Dnmt1. I describe the first in vivo mouse model in which Dnmt3b compensates for loss of
Dnmt1 in somatic cells. Following Dnmt1 ablation in the adult intestine and acute loss of Dnmt1,
Dnmt3b activity is induced, and methylation of repetitive elements is restored. However, if
Dnmt3b is ablated concurrently with Dnmt1, restoration of DNA methylation is prevented,
resulting in massive DNA damage, and cell death (Figure 4.12 G-I). These results provide
convincing evidence that Dnmt3b can contribute to maintenance DNA methylation in somatic
tissues, and strongly suggest that the categories of ‘de novo’ (Dnmt3a and 3b) versus
‘maintenance’ (Dnmt1) methylation are more plastic than traditionally thought.
In conclusion, I show that deletion of Dnmt1 in the adult intestinal epithelium of Apc

Min/+

mice causes accelerated formation of adenomas. Loss of Dnmt1 results in short-term
hypomethylation, genomic instability, and apoptosis. Dnmt3b is upregulated in response to
deletion of Dnmt1 in the adult intestine, and is required to recover DNA methylation and epithelial
integrity. Dnmt1-deficient adenomas maintain global DNA methylation, but continue to display
increased genomic instability, indicating a fundamental role for Dnmt1 in preserving genomic
integrity in the intestinal epithelium.
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Figure 4.1. Analysis of Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice.

VillinCreERT2 activity was induced with three daily intraperitoneal injections of 1.6mg tamoxifen
(TAM) in four-week old Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutant and Apc

Min/+

;Dnmt1

loxP/loxP

control mice. To evaluate tumor development, the small intestine and colon were harvested at
one month and two months following tamoxifen injections, corresponding to two months and three
months of age, respectively. Acute effects of Dnmt1 ablation were analyzed by harvesting the
small intestine and colon one week following tamoxifen administration, at five weeks of age.
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Figure 4.2. Deletion of Dnmt1 in adult Apc
Apc

Min/+

;Dnmt1

loxP/loxP

mice and Apc

Min/+

Min/+

mice accelerates adenoma initiation.

;Dnmt1

loxP/loxP

;VillinCreERT2 mice were injected with

tamoxifen at 4 weeks of age. Intestines were harvested two months or one month following
tamoxifen treatment, corresponding to three months and two months of age, respectively.
(A,B) Dnmt1 deletion is maintained two months after tamoxifen treatment in the adult mouse
small intestinal epithelium. Immunohistochemical staining of Dnmt1 protein is evident in the crypts
of Apc

Min/+

;Dnmt1

loxP/loxP

(A) but absent in Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 (B) mice.

(C,D) Dramatic increase in tumor formation observed in the three-month old Dnmt1-deficient
small intestine. Hematoxylin and Eosin staining shows disruption of normal intestinal epithelial
morphology throughout the entire length of the small intestine in
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice (D) compared to Apc

Min/+

;Dnmt1

tamoxifen-treated

loxP/loxP

mice (C). Arrows

point to adenomas.
(E) Dnmt1 deletion causes increased incidence of macroscopic tumors in three-month old mice.
Total number of macroscopic tumors was counted throughout the entire small intestine in
tamoxifen-treated Apc

Min/+

;Dnmt1

loxP/loxP

mice and Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice at two

(n≥5) and three (n≥17) months of age.
(F) Neoplastic lesions found in Dnmt1-deficient mice are predominantly adenomas. Total number
of lesions displaying gastrointestinal intraepithelial neoplasia (GIN) and adenoma as determined
by histopathological scoring were counted in three-month old mice (n=3-8 per group).
(G) Dnmt1 deletion causes increased size of neoplastic lesions in the small intestine at three
months of age. Neoplastic lesions were measured in tamoxifen-treated Apc
and Apc

min/+

;Dnmt1

loxP/loxP

Min/+

;Dnmt1

loxP/loxP

mice

;VillinCreERT2 mice at two (n≥24 ) and three (n≥9) months of age.

(H) Increased number of microadenomas in the two-month old Dnmt1-deficient small intestine.
Total numbers of microadenomas were counted throughout the entire small intestine in
tamoxifen-treated Apc

Min/+

;Dnmt1

loxP/loxP

mice and Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice at two

months of age (n≥5 per group). For all graphs, data are presented as average±SEM; *P<0.05,
**P<0.01, ***P<0.001 by two-tailed Student’s t-test. Scale bars are 50µm.
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Figure 4.3. Dnmt1 deletion causes increased incidence of microadenomas in the colon at
three months.
(A,B) Dnmt1 deletion was maintained two months after tamoxifen treatment in the adult mouse
colonic epithelium. Immunohistochemical staining of Dnmt1 protein is evident in the crypts of
Apc

Min/+

;Dnmt1

loxP/loxP

Apc

Min/+

;Dnmt1

loxP/loxP

colonic

epithelia

(A),

but

is

completely

absent

in

;VillinCreERT2 mutant colon (B).

(C,D) Increased incidence of neoplastic crypts observed in three-month old Dnmt1-deficient
colons. β-catenin staining shows an example of a microadenoma (arrow) with nuclear
accumulation of β-catenin in Apc

Min/+

;Dnmt1

loxP/loxP

;Villin-Cre-ERT2 mice (D) compared to

localization on the cell membrane in the nontransformed colonic epithelia of Apc

Min/+

;Dnmt1

loxP/loxP

mice (C). Scale bars are 50µm.
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Figure 4.4. Dnmt1-deficient tumors display increased Wnt signaling.
The
Apc

small
Min/+

;Dnmt1

intestine
loxP/loxP

was

collected

from

three-month

;VillinCreERT2 mutants and Apc

Min/+

;Dnmt1

and

loxP/loxP

two-month

old

controls, which were

tamoxifen-treated at four weeks of age. Immunostaining for several Wnt targets was performed to
characterize Wnt pathway activation in mutant compared to control tumors. At two months,
Dnmt1-deficient tumors already exhibit increased Wnt signaling in tumors (B,E,F) relative to
control tumors at three months (A,D,G).
(A-C) Immunohistochemical staining reveals increased nuclear β-catenin in three-month old
Apc

Min/+

;Dnmt1

loxP/loxP

intestine (A). Apc

;VillinCreERT2 mutant (C) compared to Apc

Min/+

;Dnmt1

loxP/loxP

Min/+

;Dnmt1

loxP/loxP

control small

;VillinCreERT2 mutant tumors at two months of age (B) show

similar levels of nuclear β-catenin compared to Apc

Min/+

;Dnmt1

loxP/loxP

(A) tumors at three months.

(D-I) Wnt signaling target CycD1 is increased in three-month old Dnmt1-deficient tumors (F)
relative to control tumors (D). Similarly sized tumors express comparable levels of CycD1
(compare D to E). CycD1 (red), DAPI (blue).
(G-I) Three-month old Dnmt1-deficient tumors exhibit increased Sox9 levels (I) compared to
control tumors (G). Similarly sized tumors display comparable levels of Sox9 (compare G to H).
Sox9 (red), DAPI (blue). Scale bars are 50µm.
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Figure 4.5. Loss of Dnmt1 affects genome stability, but not tumor cell proliferation.
(A) Percentage of cells in mitosis was determined by immunostaining and counting of the
+

phospho-H3 positive (pH3 ) nuclei in tumors at two months and three months of age. At both time
points, tamoxifen-treated Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 and Apc

Min/+

;Dnmt1

loxP/loxP

displayed

+

comparable percentages of pH3 cells, indicating that loss of Dnmt1 does not affect mitotic rates
in the small intestine.
(B-D) Cell proliferation, as visualized by immunohistochemical staining of Ki67, is similar in
tamoxifen-treated Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 (C,D) compared to Apc

Min/+

;Dnmt1

loxP/loxP

(B) small intestine.
(E-G) Neoplastic epithelia contain TUNEL-positive cells at low frequency (yellow arrows) in
Apc

Min/+

;Dnmt1

loxP/loxP

Apc

Min/+

;Dnmt1

loxP/loxP

mice

(E),

which

is

unchanged

in

tamoxifen-treated

;VillinCreERT2 mice (F,G). TUNEL (red), E-cadherin (green), DAPI (blue).

(H-J) The number of neoplastic epithelial cells positive for DNA double-strand breaks, as
visualized by immunofluorescence staining of γH2AX, is increased in tamoxifen-treated
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice (I,J) compared to Apc

Min/+

;Dnmt1

loxP/loxP

(H) small

intestines. This is not due to accelerated growth, because similarly sized tumors also show
increased γH2AX in Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 (I) compared to Apc

Min/+

;Dnmt1

loxP/loxP

(H). All scale bars: 50µm.
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Figure 4.6. Dnmt1 deletion in Apc

Min/+

mice causes massive epithelial remodeling within

one week.
Dnmt1
Apc

loxP/loxP

Min/+

(A),

;Dnmt1

loxP/loxP

Dnmt1

loxP/loxP

;VillinCreERT2

(B),

Apc

Min/+

;Dnmt1

loxP/loxP

(C),

and

;VillinCreERT2 (D) intestinal epithelium one week after tamoxifen injection.

Hematoxylin and Eosin staining demonstrates increased severity of the Dnmt1 mutant phenotype
on the Apc

Min/+

background (D) versus control (B).

(E-H) Immunohistochemistry for Dnmt1 confirms loss of protein in both tamoxifen-treated
Dnmt1

loxP/loxP

;VillinCreERT2 (F) and Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutants (H).

(I-L) Co-staining for Ki67 (red), a marker of proliferation, and γH2AX (green), which marks DNA
double-stranded
Dnmt1

loxP/loxP

breaks.

Both

control

genotypes

(I,K)

have

minimal

γH2AX

foci.

;VillinCreERT2 mutants have increased proliferation (J), as previously reported

(Sheaffer, Kim et al. 2014). Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mutants (L) have regions with

decreased levels of Ki67 and display an increased number of γH2AX foci, reflecting elevated
genomic instability immediately following Dnmt1 ablation. See also Figure S1.
(M-P) TUNEL staining to detect apoptosis (red) with E-cadherin (green) to outline the epithelium.
Controls display no apoptotic nuclei in crypt cells (M,O). Both Dnmt1-mutant genotypes (N,P)
display increased apoptosis, although there are noticeably more apoptotic nuclei in
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 crypts (P) compared to Dnmt1

loxP/loxP

;VillinCreERT2 crypts

(N).
Scale bars in (A-D) are 100µm. Scale bars in (E-P) are 50µm.
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Figure 4.7. DNA methylation dynamics after acute Dnmt1 deletion.
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice and Apc

Min/+

;Dnmt1

loxP/loxP

controls were tamoxifen-

treated at four weeks of age. The intestines were harvested at five weeks (A) or three months (B)
of age, corresponding to one week and two months post-tamoxifen treatment, respectively. Crypt
epithelium (A,B) or visible adenomas (B) were isolated by laser capture microdissection. Targeted
bisulfite sequencing of nine CpGs in the LINE1 repetitive elements was performed to estimate
global methylation levels.
(A) Five-week old Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 intestinal crypts exhibit significantly

reduced LINE1 methylation levels compared to Dnmt1

loxP/loxP

;Apc

Min/+

control crypts (n=3-4 per

group).
(B) No difference in methylation at the LINE elements was detected in normal and tumor cells
from three-month old Apc

Min/+

;Dnmt1

loxP/loxP

and Apc

Min/+

;Dnmt1

loxP/loxP

; VillinCreERT2 mice treated

with tamoxifen at four weeks of age (n=3-11 per group).
For all graphs, data are presented as average±SEM. ***P<0.001 by two-tailed Student’s t-test.
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Figure 4.8. Methylation profiling of H19 ICR following Dnmt1 ablation.
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice and Apc

Min/+

;Dnmt1

loxP/loxP

controls were tamoxifen-

treated at four weeks of age. Intestine was harvested at five weeks (A) or three months (B) of
age, corresponding to one week and two months post-tamoxifen treatment, respectively. Crypt
epithelium or visible adenomas were isolated by laser capture microdissection. Targeted bisulfite
sequencing of six CpGs in the H19 imprinting control region (ICR) was performed to estimate
maintenance methylation.
(A) H19 ICR methylation is preserved in five-week old Dnmt1-mutant Apc
Dnmt1

loxP/loxP

;Apc

Min/+

Min/+

crypts, similar to

control crypts. Average±SEM; (n=3-4).

(B) No change in H19 ICR methylation is detected in normal and tumor cells from tamoxifentreated, three-month old Apc

Min/+

;Dnmt1

loxP/loxP

and Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice.

Average±SEM; (n=3-11).
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Figure 4.9. Dnmt1-deficient tumors do not express Dnmt1 protein.
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 and Apc

Min/+

;Dnmt1

loxP/loxP

mice were tamoxifen-treated at

four weeks of age. Dnmt1 immunohistochemistry was performed in three-month old intestines to
confirm ablation of Dnmt1 in Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 intestinal tumors (B and B’),

relative to controls (A and A’). Dnmt1 is expressed in control three-month old adenomas (A, see
inset in A’), and is not present in age-matched Dnmt1-deficient adenomas (B, see inset B’). Scale
bars are 50µm.
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Figure 4.10. Dnmt3b is upregulated one week following Dnmt1 ablation.
Dnmt3a
Apc

Min/+

(A,B)

;Dnmt1

loxP/loxP

and

Dnmt3b

(C,D)

;VillinCreERT2 mutant and Apc

immunofluorescent
Min/+

;Dnmt1

loxP/loxP

staining

in

control intestinal epithelium

at one week post-tamoxifen injection. Inset shows 20X image of stained crypt epithelium. Dnmt3a
levels in mutants (B) are similar to controls (A). Dnmt3b protein levels are increased in mutant
crypts (D) compared to control crypts (C). Scale bars are 50µm.

	
  

	
  

130	
  

	
  

	
  

131	
  

Figure 4.11. Dnmt3b is required to maintain DNA methylation and epithelial integrity in the
absence of Dnmt1.
Loss of Dnmt1 and Dnmt3b in Apc

Min/+

mice causes increased apoptosis and is not compatible

with life.
(A,B) Hematoxylin and eosin staining reveals increased epithelial disorganization one week after
tamoxifen injection in Apc
Apc

Min/+

;Dnmt1

loxP/loxP

Min/+

;Dnmt3b

;Dnmt1

loxP/loxP

loxP/loxP

;Dnmt3b

loxP/loxP

;VillinCreERT2 mutants compared to

controls.

(C,D) Dnmt1 and (E,F) Dnmt3b protein staining confirms ablation of respective proteins in the
intestinal epithelium of five-week old Apc

Min/+

;Dnmt1

loxP/loxP

;Dnmt3b

loxP/loxP

;VillinCreERT2 mutants.

(G,H) Co-staining for Ki67 (red), a marker of proliferation, and γH2AX (green), which marks DNA
double-strand breaks. Apc

Min/+

;Dnmt1;Dnmt3b;VillinCreERT2 mutants (H) have decreased Ki67

staining and increased γH2AX foci compared to controls (G).
(I,J) Costaining of TUNEL (red), to mark apoptotic nuclei, and Epcam (green) to outline the
epithelium. Apc

Min/+

;Dnmt1;Dnmt3b;VillinCreERT2

mutants (J) have increased apoptosis

compared to controls (I). Scale bars are 50µm.
(K) Dnmt1; Dnmt3b deficient Apc

Min/+

mice are not viable. Percent survival of mice of the indicated

genotypes following tamoxifen injection (TAM) at four weeks of age. *P<0.05, ***P<0.00001, by
log rank test (n≥7 per group).
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Figure 4.12. Functional analyses of DNA methylation in Apc

Min/+

cancer development.

Mice and intestinal epithelium in (A-D,F,G) are shown in black, representing normal DNA
methylation levels. The intestinal epithelium in (E,H) is white, indicating acute hypomethylation.
(A-C) Apc

Min/+

;Dnmt1

loxP/loxP

control mice maintain DNA methylation in all tissues, including the

intestinal epithelium. At five weeks, mice display normal DNA methylation levels, and no tumor
formation (B). At three months of age, Apc

Min/+

;Dnmt1

loxP/loxP

intestine has preserved DNA

methylation, and harbors multiple adenomas (C, adenomas are outlined in green).
(D-F) In the current study, intestine-specific ablation of Dnmt1 was induced in four-week old
Apc

Min/+

;Dnmt1

loxP/loxP

;VillinCreERT2 mice (D). Mice displayed acute global hypomethylation and

increased genome instability in the intestine at five weeks of age (E, red circles indicate DNA
damage). At three months of age, mice had recovered global DNA methylation, but exhibited
significantly more tumors compared to controls (F, large adenomas outlined in green). These
tumors also displayed increased genomic instability (F), distinct from control tumors at the same
time point (C).
(G-I) Loss of both Dnmt3b and Dnmt1 in the adult intestinal epithelium was induced using
Apc

Min/+

;Dnmt1

loxP/loxP

;Dnmt3b

loxP/loxP

;VillinCreERT2 mice (G). Five-week old mice displayed

severe hypomethylation and genome instability (H). Mice failed to recover and died within 21
days of Dnmt1/Dnmt3b ablation (I).
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Chapter 5
Conclusions and Future Directions
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Summary and Conclusions
I have shown that Dnmt1 is an essential regulator of genomic stability in the murine
intestinal epithelium. Loss of Dnmt1 in the neonatal intestine causes hypomethylation, irreparable
DNA damage, and apoptosis of progenitor cells. As a result, these mice do not compete well for
maternal resources, and die before weaning. Dnmt1 ablation in the adult intestinal epithelium also
results in acute DNA hypomethylation and DNA damage. However, the adult Apc

Min/+

intestine

compensates for these aberrations by increased Dnmt3b activity, and recovers normal DNA
methylation levels within two months of Dnmt1 ablation. These results have implications for
several fields of research, which I outline below.

Neonatal intestinal progenitors and adult intestinal stem cells are distinct cell populations,
with differing requirements for Dnmt1
I have demonstrated that Dnmt1 is required to varying degrees in the intestinal
epithelium, dependent on the stage of intestinal maturity. Dnmt1 is required to maintain progenitor
cells in the neonatal intestinal epithelium, and loss of Dnmt1 during intestinal development results
in perinatal lethality. Dnmt1 ablation in the adult intestinal epithelium also results in acute DNA
hypomethylation and DNA damage, but is not essential for intestinal epithelial survival, as
reported previously (Sheaffer, Kim et al. 2014). Interestingly, the adult intestine recovers DNA
methylation following the immediate effects of Dnmt1 deletion, indicating a distinct difference in
the requirement of Dnmt1 in the developing, in comparison to mature, intestinal epithelium. The
distinct adult and perinatal Dnmt1-mutant phenotypes are not an artifact of differential Cre
transgene activity, because tamoxifen-treated Dnmt1

loxP/loxP

;VillinCreERT2 neonatal mice also

exhibit decreased viability (data not shown). Therefore, these data indicate important differences
in proliferative processes in the developing versus adult intestinal epithelium.
It is important to consider that the murine neonatal intestine is comparable to ~10 weekold human fetal intestine (Montgomery, Mulberg et al. 1999). Thus, the mouse intestine at birth is
not fully mature, and the intestinal stem cell niche is not equivalent to the crypts found in adult
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intestinal epithelium. Indeed, I discovered that the rate of proliferation in the perinatal intestine is
dramatically increased compared to adult intestinal epithelium, similar to that reported by other
groups (Figure 3.13; (Itzkovitz, Blat et al. 2012)). Wnt signaling, which is required to maintain
proliferation in adult intestinal epithelial crypts, is not necessary in the developing intestine until
after nascent villus formation at E15.5 (Korinek, Barker et al. 1998). Recent studies of intestinal
organoid cultures derived from late-gestation and neonatal mouse intestine have further
supported the notion that intervillus progenitors in the neonate are distinct from the crypt-basedcolumnar stem cell population in the adult (Fordham, Yui et al. 2013, Mustata, Vasile et al. 2013).
In vitro, mature crypts form organoids with budding outgrowths that are anomalous to intestinal
crypts in vivo. Although progenitors from embryonic and neonatal intestinal epithelium also form
budding organoids in vitro, nearly half of late gestation intestinal progenitors form spheroids
(Fordham, Yui et al. 2013, Mustata, Vasile et al. 2013). Spheroids are small cysts of proliferative
intestinal cells, which do not produce buds during prolonged culture. Expression of Wnt signaling
factors correlates with progenitor maturation and budding-organoid formation: in contrast to
organoids derived from adult crypts, progenitors isolated from embryonic stages prior to E18.5
express low levels of Wnt, and form spheroids in culture (Fordham, Yui et al. 2013). Differing
requirements for Wnt signaling during development indicate distinct regulation of proliferation and
progenitor cell expression programs.
The differential requirement for Dnmt1 and DNA methylation during development relative
to fully mature organs may be a global event not limited to the intestinal epithelium. In the
developing pancreas, Dnmt1 is required to prevent p53-dependent apoptosis (Georgia et al),
whereas in the mature pancreas, Dnmt1-mediated methylation is required to maintain endocrine
β-cell identity (Dhawan et al Dev Cell 2011). It will be interesting to determine the requirements
for Dnmt1 in other organs, both during development and in the adult organ, which will help
elucidate the mechanisms underlying tissue-specific epigenetic regulation.
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Dnmt1 and DNA methylation are essential for genomic stability in the intestinal epithelium
My results indicate that loss of Dnmt1 in the perinatal, adult, and cancer-prone Apc

Min/+

intestinal epithelia causes an increase in double strand breaks, demonstrating that Dnmt1 is
essential for maintaining genome integrity in the small intestine. Deletion of Dnmt1 induces
hypomethylation and genomic instability in various cell types in vitro, including mouse ES cells,
mouse embryonic fibroblasts, and human HCT116 colorectal cancer cell lines. Dnmt1
hypomorphic mice exhibit increased chromosomal duplications and rearrangements, and develop
invasive T-cell lymphomas at approximately four months of age. It is important to note that these
effects are not restricted to DNMT1 deficiency. Loss of Dnmt3b also induces hypomethylation and
chromosomal instability in mouse embryonic fibroblasts (Dodge, Okano et al. 2005), suggesting
that both Dnmt1 and Dnmt3b are crucial for maintaining DNA methylation and preserving genome
integrity. Mutations in DNMT3B underlie Immunodeficiency, Centromeric region instability, and
Facial anomalies (ICF) syndrome and cause hypomethylation at centromere-adjacent
heterochromatin, leading to chromosomal translocations and deletions (Hansen, Wijmenga et al.
1999, Xu, Bestor et al. 1999). My studies corroborate these findings, further establishing that
DNA methylation is crucial to maintaining genomic stability.
Chromosomal instability also correlates with DNA hypomethylation in sporadic human
colorectal cancer (CRC) (Lengauer, Kinzler et al. 1997, Rodriguez, Frigola et al. 2006). Although
hypomethylation occurs early in human CRC development (Feinberg and Vogelstein 1983,
Gama-Sosa, Slagel et al. 1983, Goelz, Vogelstein et al. 1985, Feinberg, Gehrke et al. 1988), it is
largely unknown to what extent loss of DNA methylation contributes to tumor progression. The
majority of DNA methylation CRC research has focused on the hypermethylation of tumor
suppressor gene promoters, which is known to cause decreased expression of genes important
for mismatch repair and cell cycle control (Esteller 2005). These early studies suggested that
tumor suppressor gene hypermethylation is a key step in tumor progression, in both human CRC
and relevant mouse models (Esteller, Corn et al. 2001, Eads, Nickel et al. 2002).
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The Apc

Min/+

mouse recapitulates the human familial adenomatous polyposis (FAP)

syndrome (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992), and is commonly utilized as an in
vivo model for human CRC. FAP patients and Apc

Min/+

mice have only one functional copy of the

Apc gene. Apc is a critical component of the cytoplasmic β-catenin destruction complex, and loss
of Apc allows increased nuclear β-catenin localization, Wnt pathway stimulation, and uncontrolled
cell proliferation (Pinto, Gregorieff et al. 2003, Sansom, Reed et al. 2004). Thus, loss of
heterozygosity (LOH) at the Apc locus triggers tumor development (Su, Kinzler et al. 1992,
Luongo, Moser et al. 1994). Apc

Min/+

mice develop multiple tumors in the small intestine by three

months of age (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992), and have served as an efficient
model for in vivo studies of intestinal tumor development and progression.
Several studies have employed global hypomorphic Dnmt1 alleles in Apc
report that Dnmt1 is required for tumor progression in the Apc

Min/+

Min/+

mice, and

model (Laird, Jackson-Grusby

et al. 1995, Cormier and Dove 2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada,
Jackson-Grusby et al. 2005). These reports are ultimately inconclusive due to possible intestineindependent or developmental effects of decreased Dnmt1 expression. Indeed, my own work
demonstrates that Dnmt1 is essential for maintenance of perinatal intestinal progenitor cells. Our
lab also found that global loss of the mesenchymal transcription factor Foxl1 increases intestinal
tumor load in Apc

Min/+

mice (Perreault, Sackett et al. 2005), demonstrating that Apc

Min/+

tumor

multiplicity is influenced by factors not expressed in the intestinal epithelium. The reduced
tumorigenesis phenotypes previously described in Dnmt1-hypomorphic Apc

Min/+

mice are likely

due to decreased proliferation of progenitor cells in the neonatal intestine, which would provide
fewer opportunities for tumor initiation. Alternatively, increased genomic instability in these mice
from early development onward may actually prohibit tumor progression via increased levels of
apoptosis in damaged cell populations (Halazonetis, Gorgoulis et al. 2008). In the adult intestinal
epithelium, inducible deletion of Dnmt1 causes acute hypomethylation of intestinal stem cell
genes and two-fold expansion of the proliferative crypt zone (Sheaffer, Kim et al. 2014), which
suggests that hypomethylation promotes proliferative processes in the intestinal epithelium.
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Intestinal tumor progression could be due in part to the incomplete differentiation caused by
hypomethylation, and ablation of Dnmt1 may exacerbate this process.
To directly determine the function of epithelial Dnmt1 in intestinal tumorigenesis, I
employed an intestine-specific, inducible ablation model to delete Dnmt1 in Apc

Min/+

mice. In stark

contrast to the previously published studies, I observed increased tumorigenesis two months
following intestinal epithelial-specific ablation of Dnmt1 in four-week old Apc

Min/+

mice. As

predicted by my preceding work, Dnmt1-ablated tumors displayed multiple γH2AX foci, a marker
of DNA double-strand breaks and genomic instability. I also noted increased microadenoma
formation, indicating an accelerated rate of tumor initiation, although the proliferation rate of
neoplastic cells was not altered relative to controls. To determine the underlying mechanism of
this increased tumor load, I analyzed mice one week following Dnmt1 deletion, and observed
global hypomethylation and increased levels of DNA damage and crypt cell apoptosis relative to
controls. Apc

Min/+

mice have weakened responses to stressors, such as irradiation (Tao, Tang et

al. 2015), and I show that loss of Dnmt1 in Apc

Min/+

mice precipitates massive epithelial damage

and remodeling. Previously, Yamada and colleagues reported that Dnmt1-hypomorphic Apc

Min/+

mice displayed an increased number of microadenomas (2005). They concluded that loss of
Dnmt1 augmented LOH at the Apc locus, but did not provide a satisfying mechanism to explain
this phenotype. I propose that the genomic instability induced following loss of Dnmt1 increases
LOH, resulting in accelerated tumorigenesis and ultimately larger tumors.
My results indicate that hypomethylation is a strong instigator of tumor development, as
hypomethylation causes genomic instability, driving accelerated LOH at the Apc locus and
increased tumorigenesis. As global hypomethylation correlates with chromosomal instability in
CRC (Lengauer, Kinzler et al. 1997, Rodriguez, Frigola et al. 2006), and loss of Dnmt1 leads to
increased chromosomal translocations and instability in several contexts (discussed above), it is
possible that early genomic hypomethylation induces genomic instability. Thus, loss of Dnmt1
could contribute to the accumulation of multiple mutations during development from adenoma to
carcinoma. Future work will determine the precise function of DNA hypomethylation in early tumor
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formation, using both in vivo mouse models and patient-derived in vitro organoids. The CRISPRCas9 genome editing technology has been optimized for human intestinal organoid culture, and
was utilized to mutate genes with putative roles in CRC development (Matano, Date et al. 2015).
Mutated organoids were engrafted under the kidney capsule in immune-deficient mice to test
tumor formation in vivo (Matano, Date et al. 2015). These models can be utilized and combined
with next-generation sequencing technologies to precisely assess how hypomethylation
contributes to genomic instability at different stages of CRC, and if genomic hypomethylation in
mouse models has the same effect as in human CRC.

Dnmt3b can compensate for Dnmt1 in the intestinal epithelium in vivo
Strikingly, by two months post-Dnmt1 ablation, DNA methylation levels at repetitive
elements in Dnmt1-deficient Apc

Min/+

tumors and adjacent epithelia were comparable to controls.

These results were also confirmed by immunofluorescent staining with a 5-methylcytosine
antibody (data not shown). I hypothesized that the de novo methyltransferases (Dnmt3a and
Dnmt3b) become activated following Dnmt1 deletion, and are necessary for remethylation of the
genome and phenotypic recovery. Indeed, I observed increased Dnmt3b protein levels in Dnmt1deficient Apc

Min/+

intestinal crypts, relative to Apc

requirement for Dnmt3b in the survival of Apc

Min/+

Min/+

;Dnmt1

controls. Accordingly, I tested the

loxP/loxP

;VillinCreERT2 tamoxifen-treated

mice. Strikingly, when I deleted Dnmt1 and Dnmt3b concurrently in the Apc

Min/+

intestinal

epithelium, these mice were unable to recover, and died within three weeks of tamoxifen
administration. Compared to Dnmt1-mutant Apc

Min/+

mice, Dnmt1;Dnmt3b-deficient Apc

Min/+

mice

displayed extensive DNA damage and high levels of crypt cell apoptosis. These results clearly
demonstrate that Dnmt3b is required to recover and maintain DNA methylation in the intestinal
epithelium of Dnmt1-deficient Apc

Min/+

mice. Importantly, my data directly contradict the current

DNA methylation dogma, and provide a novel in vivo model for Dnmt1 compensation by a de
novo methyltransferase.
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In the field of DNA methylation, it is standard to refer to Dnmt1 as the ‘maintenance’
methyltransferase, whereas Dnmt3a and Dnmt3b are termed the ‘de novo’ methyltransferases.
My data strongly suggest that these definitions need to be revised to better reflect the current
body of literature. It has been suggested that all replicating somatic cells require Dnmt1 for cell
survival (Liao, Karnik et al. 2015). I demonstrate that this is not the case in the mature intestinal
epithelium, one of the most highly self-renewing tissues in mammals. My work corroborates in
vitro evidence showing that loss of Dnmt1 does not lead to complete hypomethylation (Li, Bestor
et al. 1992). In some cases, de novo methyltransferases are essential for methylation of certain
elements or enhancers, and cannot be compensated for by Dnmt1. For example, hematopoietic
stem cells (HSCs) require Dnmt3a for normal self-renewal and differentiation processes (Challen,
Sun et al. 2012). Loss of Dnmt3a in HSCs causes demethylation at essential stem cell genes,
inducing hyper-proliferation and reducing differentiation rates (Challen, Sun et al. 2012). Dnmt3b
also contributes to silencing of germline genes in somatic cells (Velasco, Hubé et al. 2010), and
maintenance methylation in ES cells (Liang, Chan et al. 2002, Chen, Ueda et al. 2003). My
results provide additional evidence that the de novo methyltransferase Dntm3b can perform
maintenance methylation in vivo.
In the future, to determine by which molecular mechanism Dnmt3b is functioning as a
‘maintenance’ methyltransferase, I could take advantage of the mouse models described in
Chapter 4, in which Dnmt1 is inducibly ablated in the adult Apc
experiments, Apc

Min/+

;Dnmt1

loxP/loxP

Min/+

intestinal epithelium. In these

;VillinCreERT2 (mutant) and Apc

Min/+

;Dnmt1

loxP/loxP

(control)

mice are tamoxifen-treated at four weeks of age to induce Dnmt1 deletion, and intestinal crypts
are harvested one week and two months following tamoxifen injection. These time points enable
observation of acute DNA hypomethylation immediately following Dnmt1 ablation compared to
the long-term recovery of DNA methylation, which requires Dnmt3b. Whole-genome bisulfite
sequencing from control and mutant intestinal crypts at these two time points following Dnmt1
deletion would reveal how methylation patterns are decreased and subsequently recovered over
time. ChIP-Seq for Dnmt1 and Dnmt3b from these cohorts of mice would allow me to characterize

	
  

	
  

142	
  

compensation by Dnm3b in mutant crypts. At one week following Dnmt1 ablation, I would predict
to see loss of Dnmt1 localization in mutant crypts, and normal Dnmt3b distribution, relative to
respective ChIP-Seq of control crypts. Following recovery of DNA methylation at two months post
Dnmt1 deletion, I would expect Dnmt3b ChIP-Seq profiles from mutants to mimic Dnmt1 ChIPSeq profiles in control crypts. To elucidate the mechanism underlying Dnmt3b maintenance
methylation, I could perform immunoprecipitation of Dnmt3b, followed by mass spectrometry to
identify the protein complexes associated with Dnmt3b in mutant crypts, compared to controls.
Mutant crypts may exhibit differential Dnmt3b binding at two months post-Dnmt1 ablation,
compared to control crypts and mutant crypts at one week following tamoxifen treatment. These
experiments would define how DNA methylation and Dnmt binding profiles change during the
course of DNA methylation loss and recovery, and provide an exciting model to analyze drastic
chromatin alterations in vivo.

Future Directions: An Epigenetic Map of Intestinal Differentiation
My research has significance in multiple fields. In intestinal biology, my work strongly
suggests distinct differences between developing and mature crypts. Understanding crypt
development is essential for developing new cancer therapeutics targeting aberrant stem cell
+

activity. Since the Lgr5 , CBC stem cell population is touted as being the cell of origin in
colorectal cancers (Barker, Ridgway et al. 2009, Merlos-Suárez, Barriga et al. 2011, Barker, van
Oudenaarden et al. 2012), understanding how these cells develop within the context of the
intestinal crypt is crucial to advancing intestinal disease research. Recent studies employing the
organoid mini-gut model system has also shown that embryonic and fetal intestinal progenitors
have distinct expression profiles, and form unique cyst-structures in culture (Fordham, Yui et al.
2013, Mustata, Vasile et al. 2013). Use of organoid model systems to enrich for homogenous
populations of specific cell types will be useful in studying progenitors during intestinal
development, as well as epigenetic changes that occur during mature intestinal differentiation.
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The intestinal epithelium is a remarkable system due to the high rate of cell turnover and
diversity of cell types within the compact crypt-villus architecture. Indeed, the crypt-villus subunit
is an ideal in vivo model of adult intestinal stem cell proliferation, renewal, and differentiation.
However, to fully understand how epigenetic marks interact and influence this process, we must
isolate and characterize multiple marks and transcription factor binding profiles of stem,
progenitor, and differentiated cell populations. In the past decade, many markers for specific cell
types in the intestinal epithelium have been defined, the vast majority of which label stem cells,
such as the Lgr5

+

crypt-based-columnar stem cells (CBC) (Barker, van Es et al. 2007).

Fluorescent-activated cell sorting (FACS) isolation of CBCs is feasible by utilization of knock-in
mice, which express fluorescent proteins downstream of stem cell gene promoters (Barker, van
Es et al. 2007). This has enabled transcriptome sequencing, whole-genome bisulfite sequencing,
and ChIP-Seq analysis of the CBC stem cell population (Merlos-Suárez, Barriga et al. 2011,
Kaaij, van de Wetering et al. 2013, Kim, Li et al. 2014, Sheaffer, Kim et al. 2014). Progenitor cell
populations can also be isolated using genetic mouse models. For instance, Notch-deficient mice
display increased secretory progenitors in crypts; these crypt cells can be isolated using EDTA
dissociation methods (Kim, Li et al. 2014). Differentiated cells can be selected for using similar
genetic methods, such as loss of Atoh1 to enrich for enterocytes in villi (Kim, Li et al. 2014).
These methods have been utilized in several reports that describe differences in
epigenetic marks and transcription factor binding between CBC, progenitor, and differentiated
cells (Verzi, Shin et al. 2013, Kim, Li et al. 2014, Sheaffer, Kim et al. 2014). These studies have
indicated a major role for transcription factors, such as Cdx2, in maintenance of chromatin
profiles during intestinal differentiation (Verzi, Shin et al. 2013, Kim, Li et al. 2014), and a function
for DNA methylation in restricting the proliferative cell region (Sheaffer, Kim et al. 2014).
Interestingly, all of these reports found that the most dynamic regions of epigenetic control are
associated with enhancer marks, including H3K27ac and H3K4me2. Although many epigenetic
marks have been profiled in intestinal cells, a broad study profiling multiple repressive
(H3K27me3, H3K9me3) and activating marks (H3K4me3, H3K79me2, H3K36me3) in all of the
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intestinal cell sub-populations has not yet been published. A complete and detailed epigenomic
map of intestinal differentiation will be an invaluable tool in the study of intestinal development,
homeostasis, and disease.
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